WO2012016980A2 - Use of sigma ligands in opioid-induced hyperalgesia - Google Patents

Use of sigma ligands in opioid-induced hyperalgesia Download PDF

Info

Publication number
WO2012016980A2
WO2012016980A2 PCT/EP2011/063286 EP2011063286W WO2012016980A2 WO 2012016980 A2 WO2012016980 A2 WO 2012016980A2 EP 2011063286 W EP2011063286 W EP 2011063286W WO 2012016980 A2 WO2012016980 A2 WO 2012016980A2
Authority
WO
WIPO (PCT)
Prior art keywords
dichlorophenyl
pyrazol
yloxy
substituted
methyl
Prior art date
Application number
PCT/EP2011/063286
Other languages
French (fr)
Other versions
WO2012016980A3 (en
Inventor
José Miguel VELA HERNÁNDEZ
Daniel Zamanillo-Castanedo
Margarita Puig Riera de Conias
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201302559A priority Critical patent/UA110213C2/en
Priority to NZ606539A priority patent/NZ606539A/en
Priority to KR1020137005269A priority patent/KR101855357B1/en
Priority to EP11738245.7A priority patent/EP2600863B1/en
Priority to AU2011287627A priority patent/AU2011287627B2/en
Priority to SG2013007752A priority patent/SG187668A1/en
Priority to CN201180038322XA priority patent/CN103052388A/en
Priority to CA2807069A priority patent/CA2807069C/en
Priority to RU2013109291/15A priority patent/RU2589899C2/en
Priority to ES11738245.7T priority patent/ES2673729T3/en
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Priority to JP2013522233A priority patent/JP5923502B2/en
Priority to BR112013002541A priority patent/BR112013002541A2/en
Priority to US13/814,148 priority patent/US9789115B2/en
Priority to MX2013001328A priority patent/MX350828B/en
Priority to MA35700A priority patent/MA34506B1/en
Publication of WO2012016980A2 publication Critical patent/WO2012016980A2/en
Publication of WO2012016980A3 publication Critical patent/WO2012016980A3/en
Priority to TNP2013000026A priority patent/TN2013000026A1/en
Priority to ZA2013/00795A priority patent/ZA201300795B/en
Priority to IL224530A priority patent/IL224530A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to the use of sigma receptor ligands in the prevention and/or treatment of opioid-induced hyperalgesia (OIH) associated to opioid therapy, including the combination of opioids with a sigma receptor ligand for the treatment and/or prevention of OIH.
  • OIH opioid-induced hyperalgesia
  • Opiates refer to alkaloids extracted from poppy pods (Opium Poppy; Papaver Somniferum) and their semi-synthetic counterparts which bind to the opioid receptors. Basically to be called an opiate one has to either be a natural opioid receptor agonist or start the refining process with one of the natural alkaloid molecules. Once chemically altered, such as the process of converting morphine into heroin, the drug is then labeled as a semisynthetic opiate or semi-synthetic opioid - the terms can be used interchangeably.
  • Semi-synthetic opiates include heroin (diamorphine), oxycodone, hydrocodone, dihydrocodiene, hydromorphone, oxymorphone, buprenorphine and etorphine.
  • opioid is a blanket term used for any drug which binds to the opioid receptors.
  • Opioids include all of the opiates as well as any synthesized drug that bind to opioid receptors.
  • Synthetic opioids include methadone, pethidine, fentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, tramadol, tapentadol and loperamide.
  • Opioid and opiates drugs are classified typically by their binding selectivity in respect of the cellular and differentiated tissue receptors to which specific the drug binds as a ligand.
  • ORL1 opioid receptor-like
  • All the opioid receptors are G-protein coupled receptors and possess the same general structure: an extracellular N-terminal region, seven transmembrane domains and an intracellular C-terminal tail structure.
  • opioid analgesics bind to and activate selectively the opioid mu receptors; that is, they act as agonists at mu opioid receptors.
  • the sigma receptor is not regarded as an opioid receptor.
  • Opioid analgesics are recommended for the management of moderate to severe pain including that which occurs following surgery and trauma and in many patients with cancer. Apart from pain relief, opioid analgesics also produce a range of common well- known side effects (e.g., sedation, emesis, constipation, respiratori depression, dependence).
  • opioid analgesics may also activate a pro-nociceptive mechanism resulting in the phenomenon of opioid-induced hyperalgesia (OIH) [also called opioid-induced abnormal pain sensitivity].
  • OIH opioid-induced hyperalgesia
  • OIH is a recognized complication of opioid therapy characterized by enhanced pain sensitivity.
  • opioid therapy aiming at alleviating pain may render patients more sensitive to pain and potentially may aggravate their preexisting pain.
  • I n fact, OI H should be considered in the differential when opioid therapy fails.
  • any apparent decrease in opioid analgesic effectiveness may be due at least in part to the presence of OIH rather than reflecting a worsening of the disease state and/or the development of pharmacological tolerance.
  • OIH As disclosed in the art (Sandford.M. et al.; Pain Physician 2009; 12:679-684) the existence of OIH is proved by basic science evidence (Mao, J.; Pain 2002; 100:213- 217) and by clinical evidence (Guignard.B. et al.; Anesthesiology 2000; 93:409-417 and Angst, M.S. et al.; Anesthesiology 2006; 104:570-587). Additionally there are neurobiological mechanisms discussed for OI H involving the central glutaminergic system, the spinal dynorphins or the descending facilitation.
  • OIH is evidenced by individuals taking opioids, which can develop an increasing sensitivity to noxious stimuli (hyperalgesia), even evolving a painful response to previously non-noxious stimuli (allodynia).
  • Increased pain in OIH may result from one or more of the following: pain in the absence of a noxious stimulus (spontaneous pain), increased duration of pain in response to brief stimulation (ongoing pain or hyperpathia), reduced pain threshold (allodynia), increased responsiveness to suprathreshold stimulation (hyperalgesia), spread of pain and hyperalgesia to uninjured tissue (referred pain and secondary hyperalgesia), and abnormal sensations (e.g., dysesthesia, paresthesia).
  • 01 H is a phenomenon often associated with the long term use of opioids, but some studies have demonstrated that this effect can also occur after only a single dose of opioids (E. Celerier et al. , J . Neurosci. 21 , 4074-4080 (2001 )). Thus, OI H occurs following both acute and chronic opioid administration. In this way, OIH is a less recognized side effect of chronic opioid therapy. However, it is becoming more prevalent as the number of patients receiving opioids for chronic pain increases (Trescot.A.M. et al.; Pain Physician 2008; 11 :S12-S16). Increases in pain intensity can occur upon discontinuation of opioid therapy but such an abnormal increased pain sensitivity including hyperalgesia or allodynia can occur also in the absence of overt opioid withdrawal in subjects that have been administered opioid drugs.
  • Another mechanism proposed to underpin opioid-induced excitatory signaling involves stimulation of adenylate cyclase formation via G 5 -coupled opioid receptors that opposes inhibition of adenylate cyclise formation via G i/0 -coupled opioid receptors to attenuate levels of pain relief (Smith, M.T.; Acute Pain 2008; 10:199-200).
  • opioid analgesics with agents that block excitatory opioid signaling pathways can improve pain relief.
  • Some strategies include combining opioid analgesics with NMDA-receptor antagonists, such as low dose ketamine, and more recently, clinical trials have investigated combinations of ultra-low dose naltrexone (non-selective opioid antagonist) and opioid agonists such as morphine and oxycodone to selective block signaling via G 5 -coupled opioid receptors (Smith, M.T.; Acute Pain; 2008; 10; 199-200) that are useful in the prevention and/or treatment of opioid-induced hyperalgesia.
  • Sigma receptors are non-opioid receptors of great interest in pharmacology.
  • the sigma binding sites have preferential affinity for the dextrorotatory isomers of certain opiate benzomorphans, such as (+)SKF 10047, (+)cyclazocine, and (+)pentazocine and also for some narcoleptics such as haloperidol.
  • the sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of these pharmacoactive drugs.
  • SKF 10047 has nanomolar affinity for the sigma 1 ( ⁇ -1) site, and has micromolar affinity for the sigma 2 ( ⁇ -2) site.
  • Haloperidol has similar affinities for both subtypes.
  • OIH OIH
  • the present invention relates to the use of a sigma ligand as adjuvant in the opioid therapy of pain for the prevention and/or treatment of OIH associated to said opioid therapy.
  • This benefit of the invention is more evident when the sigma ligand is specifically a sigma-1 receptor antagonist, preferably in the form of a (neutral) antagonist, an inverse agonist or a partial antagonist. Therefore, one aspect of the present invention relates to a sigma ligand for use in the prevention and/or treatment of 01 H associated to opioid therapy.
  • said sigma ligand has the general formula (I):
  • N0 2 , -N CR 8 R 9 , and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group; n is selected from 1 , 2, 3, 4, 5, 6, 7 and 8; t is 1 ,2 or 3;
  • R 8 and R 9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen; or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.
  • Another aspect of this invention refers to the use of sigma ligand as defined above for the manufacture of a medicament for the prevention and/or treatment of OIH associated to opioid therapy.
  • Another aspect of the invention is a method of treatment of a patient suffering from OIH associated to opioid therapy, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand as defined above.
  • Another aspect of the invention refers to a combination of at least one sigma ligand as defined above and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of opioid- induced hyperalgesia associated to opioid therapy.
  • Figure 1 Schematic representation of experimental protocol n° 1 (co-administration studies in the perioperative period) showing the time course for the assessment of mechanical sensitization induced by plantar incision.
  • the opioid ligand was administered immediatly after the surgery in three consecutive intraperitoneally injections (every 15 minutes).
  • Paradigm 1 corresponds to a single administration of the sigma receptor ligand immediately before surgery and hence before opioid injection whereas
  • Paradigm 2 corresponds to a single administration of the sigma receptor ligand immediately after the last opioid injection.
  • n° 1 represents a preventive approach as the sigma ligand is administered in the periooperative period (before-Paradigm 1 or immediately after-Paradigm 2 the opioid administration), long before hyperalgesia develops.
  • Figure 2 It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 1 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
  • Figure 3 It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
  • Figures 2 and 3 show that administration of the sigma ligand in the perioperative period inhibits the development of mechanical allodynia when administered both before (Paradigm 1) and after (Paradigm 2) opiod administration.
  • the sigma ligand (compound n° 63) inhibits allodynia secondary to both surgery and opioid (Remifentanil) use (i.e., OIH).
  • OIH opioid
  • Figure 4 It shows the effect of Morphine (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period). Similar to previous figures showing the effect on Remifentanil use, the sigma ligand (compound n° 63) also inhibits allodynia secondary to surgery and OIH when Morphine was used.
  • Figure 5 It shows the effect of Morphine (opioid receptor agonist) and BD-1063 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (coadministration studies in the perioperative period).
  • the sigma ligand BD-1063 at 80 mg/kg also inhibits the development of OIH when Morphine was used.
  • Figure 6 Schematic representation of experimental protocol n° 3 (co-administration studies in naive rats) showing the time course for the assessment of Mechanical Sensitization (i.e., OIH) induced by opioids.
  • Figure 7 It shows the effect of Remifentanil (opioid ligand) and compound n° 63 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats).
  • the figure 7 shows the inhibitory effect of compound n° 63 on remifentanil- induced hyperalgesia.
  • the inhibitory effect on OIH is clear at 20 and 40 mg/kg.
  • Figure 8 It shows the effect of Remifentanil (opioid ligand) and compound BD-1063 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats). Si m ilar to compound n° 63, BD-1063 is able to inhibit OIH (i.e., remifentanil-induced hyperalgesia) when administered at 40 mg/kg.
  • OIH i.e., remifentanil-induced hyperalgesia
  • Figure 9 It shows the effect of Morphine (opioid ligand) and compound BD-1063 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats). Not only remifentanil- but also morphine-induced hyperalgesia is inhibited by the sigma ligand BD-1063 when co-administered to naive rats at 40 mg/kg together with the opioid.
  • Figure 10 It shows the effect of Fentanyl (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
  • Figure 11 It shows the effect of Sufentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
  • Figure 12 Schematic representation of experimental protocol n° 2 (OIH precipitated by naloxone).
  • Figure 13 It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
  • Figure 14 It shows the effect of Morphine (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
  • Figure 15 It shows the effect of Fentanyl (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
  • Figure 16 It shows the effect of Sufentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting of 1 to 12 carbon atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n- pentyl, etc.
  • Alkyl radicals may be optionally substituted by one or more substituents such as aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc.
  • Preferred alkyl radicals have from 1 to 6 carbon atoms. If substituted by aryl, it corresponds to an "Arylalkyl” radical, such as benzyl or phenethyl. If substituted by heterocyclyl, it corresponds to a "Heterocyclylalkyl” radical.
  • Alkenyl refers to a straight or branched hydrocarbon chain radical consisting of 2 to 12 carbon atoms, containing at least one unsaturation, and which is attached to the rest of the molecule by a single bond. Alkenill radicals may be optionally substituted by one or more substituents such as aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc. Preferred alkenyl radicals have from 2 to 6 carbon atoms.
  • Cycloalkyl refers to a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated, and which consist solely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl. Unless otherwise stated specifically in the specification, the term “cycloalkyl” is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.
  • Aryl refers to single and multiple aromatic ring radicals, including multiple ring radicals that contain separate and/or fused aryl groups. Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms, such as phenyl, naphthyl, indenyl, fenanthryl or anthracyl radical.
  • the aryl radical may be optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl, alkoxycarbonyl, etc.
  • Heterocyclyl refers to a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. It may be aromatic or not aromatic.
  • the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated or aromatic.
  • heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran, coumarine, morpholine; pyrrole, pyrazole, oxazole, isoxazole, triazole, imidazole, etc.
  • Alkoxy refers to a radical of the formula -OR a where R a is an alkyl radical as defined above, e. g. , methoxy, ethoxy, propoxy, etc.
  • Am i no refers to a rad ical of the form u la -NH 2 , -NHR a or -NR a R b , optionally quaternized, e.g. , methylamino, ethylamino, dimethylamino, diethylamino, propylamino, etc.
  • Halogen refers to bromo, chloro, iodo or fluoro.
  • References herein to substituted groups in the compounds of the present invention refer to the specified moiety that may be substituted at one or more available positions by one or more suitable groups, e. g.
  • alkanoyl such as a Ci_ 6 alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1 -3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl groups including those moieties having one or more sulfinyl groups including those moieties having one or more sulfinyl
  • salt must be understood as any form of an active compound used in accordance with this invention in which said compound is in ionic form or is charged and coupled to a counter-ion (a cation or anion) or is in solution.
  • This definition also includes quaternary ammonium salts and complexes of the active molecule with other molecules and ions, particularly, complexes formed via ionic interactions.
  • the definition includes in particular physiologically acceptable salts; this term must be understood as equivalent to "pharmacologically acceptable salts" or “pharmaceutically acceptable salts”.
  • pharmaceutically acceptable salts in the context of this invention means any salt that is tolerated physiologically (normally meaning that it is not toxic, particularly, as a result of the counter-ion) when used in an appropriate manner for a treatment, applied or used, particularly, in humans and/or mammals.
  • physiologically acceptable salts may be formed with cations or bases and, in the context of this invention, are understood to be salts formed by at least one compound used in accordance with the invention -normally an acid (deprotonated)- such as an anion and at least one physiologically tolerated cation, preferably inorganic, particularly when used on humans and/or mammals.
  • Salts with alkali and alkali earth metals are preferred particularly, as well as those formed with ammonium cations (NH 4 + ).
  • Preferred salts are those formed with (mono) or (di)sodium, (mono) or (di)potassium, magnesium or calcium.
  • These physiologically acceptable salts may also be formed with anions or acids and, in the context of this invention, are understood as being salts formed by at least one compound used in accordance with the invention - normally protonated, for example in nitrogen - such as a cation and at least one physiologically tolerated anion, particularly when used on humans and/or mammals.
  • This definition specifically includes in the context of this invention a salt formed by a physiologically tolerated acid, i.e.
  • salts of a specific active compound with physiologically tolerated organic or inorganic acids particularly when used on humans and/or mammals.
  • this type of salts are those formed with: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
  • solvate in accordance with this invention should be understood as meaning any form of the active compound in accordance with the invention in which said compound is bonded by a non-covalent bond to another molecule (normally a polar solvent), including especially hydrates and alcoholates, like for example, methanolate.
  • a polar solvent normally a polar solvent
  • a preferred solvate is the hydrate.
  • prodrug is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention.
  • prodrugs include, but are not limited to, derivatives and metabolites of the compounds of formula I that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid.
  • the carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule.
  • Prodrugs can typically be prepared using well-known methods, such as those described by Burger “Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001 , Wiley), “Design and Applications of Prodrugs” (H. Bundgaard ed., 1985, Harwood Academic Publishers) and Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery” Taylor & Francis (April 2002).
  • any compound referred to herein is intended to represent such specific compound as well as certain variations or forms.
  • compounds referred to herein may have asymmetric centres and therefore exist in different enantiomeric or diastereomeric forms.
  • any given compound referred to herein is intended to represent any one of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, and mixtures thereof.
  • stereoisomerism or geometric isomerism about the double bond is also possible, therefore in some cases the molecule could exist as (E)-isomer or (Z)-isomer (trans and cis isomers).
  • each double bond will have its own stereoisomerism, that could be the same as, or different to, the stereoisomerism of the other double bonds of the molecule.
  • compounds referred to herein may exist as atropisomers. All the stereoisomers including enantiomers, diastereoisomers, geometric isomers and atropisomers of the compounds referred to herein , and mixtures thereof, are considered within the scope of the present invention.
  • any compound referred to herein may exist as tautomers.
  • tautomer refers to one of two or more structural isomers of a compound that exist in equilibrium and are readily converted from one isomeric form to another. Common tautomeric pairs are amine-imine, amide-imidic acid, keto-enol, lactam-lactim, etc.
  • the compounds of the invention are also meant to include isotopically-labelled forms i.e. compounds which differ only in the presence of one or more isotopically-enriched atoms.
  • isotopically-labelled forms i.e. compounds which differ only in the presence of one or more isotopically-enriched atoms.
  • compounds having the present structures except for the replacement of at least one hydrogen atom by a deuterium or tritium, or the replacement of at least one carbon by 13 C- or 14 C-enriched carbon, or the replacement of at least one nitrogen by 15 N-enriched nitrogen are within the scope of this invention.
  • the sigma ligands, in particular the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts, solvates or prodrugs.
  • the term "pharmaceutically acceptable salts, solvates, prodrugs” refers to any salt, solvate, or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound as described herein.
  • non-pharmaceutically acceptable salts, solvates and prodrugs also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts, solvates and prodrugs.
  • the preparation of salts, solvates and prodrugs can be carried out by methods known in the art.
  • treat As used herein, the terms “treat”, “treating” and “treatment” include the eradication, removal, reversion, alleviation, modification, or control of opioid-induced hyperalgesia (OIH).
  • OIH opioid-induced hyperalgesia
  • prevention refers to the capacity of a therapeutic to avoid, minimize or difficult the onset or development of a disease or condition before its onset, in this case opioid-induced hyperalgesia (OIH).
  • OIH opioid-induced hyperalgesia
  • the method of the present invention also includes situations where the condition is completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the subject no longer experiences the condition.
  • the present method includes both preventing and managing acute and chronic OIH.
  • the terms "sigma ligand” or “sigma receptor ligand” refer to any compound binding to the sigma receptor.
  • the sigma ligand is preferebly a sigma receptor antagonist in the form of a (neutral) antagonist, an inverse agonist or a partial antagonist.
  • An "agonist” is defined as a compound that binds to a receptor and has an intrinsic effect, and thus, increases the basal activity of a receptor when it contacts the receptor.
  • An "antagonist” is defined as a compound that competes with an agonist or inverse agonist for binding to a receptor, thereby blocking the action of an agonist or inverse agonist on the receptor.
  • an antagonist also known as a “neutral” antagonist
  • Antagonists mediate their effects by binding to the active site or to allosteric sites on receptors, or they may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity.
  • Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist-receptor complex, which, in turn, depends on the nature of antagonist receptor binding.
  • a "partial antagonist” is defined as a compound that binds to the receptor and generates an antagonist response; however, a partial antagonist does not generate the full antagonist response. Partial antagonists are weak antagonists, thereby blocking partially the action of an agonist or inverse agonist on the receptor.
  • An "inverse agonist” is defined as a compound that produces an effect opposite to that of the agonist by occupying the same receptor and, thus, decreases the basal activity of a receptor (i.e., signalling mediated by the receptor). Such compounds are also known as negative antagonists.
  • An inverse agonist is a ligand for a receptor that causes the receptor to adopt an inactive state relative to a basal state occurring in the absence of any ligand.
  • an antagonist can inhibit the activity of an agonist
  • an inverse agonist is a ligand that can alter the conformation of the receptor in the absence of an agonist.
  • the sigma receptor/s as used in this application is/are well known and defined using the following citation: "this binding site represents a typical protein different from opioid, NMDA, dopaminergic, and other known neurotransmitter or hormone receptor families" (G. Ronsisvalle et al. Pure Appl. Chem. 73, 1499-1509 (2001)).
  • Pharmacological data based on ligand binding studies, anatomical distribution and biochemical features distinguish at least two subtypes of ⁇ receptors (R. Quiron et al. , Trends Pharmacol. Sci. 13, 85-86 (1992); M.L.Leitner, Eur. J. Pharmacol. 259, 65-69 (1994); S.B. Hellewell and W. D.
  • Com pound/s binding to the sigma receptor or "sigma ligand” as used in this application is/are defined as a compound having an IC 50 value of ⁇ 5000 nM, more preferably ⁇ 1 000 nM, more preferably ⁇ 500 nM on the sigma receptor. M ore preferably, the IC 50 value is ⁇ 250 nM. More preferably, the IC 50 value is ⁇ 100 nM. Most preferably, the IC 50 value is ⁇ 50 nM.
  • the half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. The IC50 is the concentration of competing ligand which displaces 50% of the specific binding of the radioligand.
  • the wording "Compound/s binding to the sigma receptor”, as used in the present application is defined as having at least >50% displacement using 10 nM radioligand specific for the sigma receptor (e.g. preferably [ 3 H]-(+) pentazocine) whereby the sigma receptor may be any sigma receptor subtype.
  • said compounds bind to the sigma-1 receptor subtype.
  • sigma ligands Compounds binding to the sigma receptor, generally also referred to as sigma ligands, are well known in the art. Many of them are encompassed by the "Compound/s binding to the sigma receptor" definition above. Although there are many known uses for sigma ligands, such as antipsychotic drugs, anxiolytics, antidepressants, stroke treatment, antiepileptic drugs and many other indications, including anti-migraine and general pain, there is no mention in the art of these compounds as useful for the treatment of opioid-induced hyperalgesia (OIH) associated to opioid therapy.
  • OIH opioid-induced hyperalgesia
  • Table 1 lists some sigma ligands known in the art (i.e. having an IC 50 ⁇ 5000 nM). Some of these compounds may bind to the sigma-1 and/or to the sigma-2 receptor. These sigma ligands also include their respective salts, bases, and acids.
  • the table above includes also reduced haloperidol.
  • Reduced haloperidol is an active metabolite of haloperidol that is produced in humans, shows a high affinity (in the low nanomolar range) for sigma-1 receptors, and produces an irreversible blockade of sigma-1 receptors both in experimental animals and human cells.
  • the sigma ligand in the context of the present invention has the general formula (I) as depicted above.
  • in the compounds of formula (I) is selected from H, - COR 8 , and substituted or unsubstituted alkyl. More preferably, is selected from H, methyl and acetyl. A more preferred embodiment is when is H.
  • R 2 in the compounds of formula (I) represents H or alkyl, more preferably methyl.
  • R 3 and R 4 in the compounds of formula (I) are situated in the meta and para positions of the phenyl group, and preferably, they are selected independently from halogen and substituted or unsubstituted alkyl.
  • both R 3 and R 4 together with the phenyl group form an optionally substituted fused ring system (for example, a substituted or unsubstituted aryl group or a substituted or unsubsituted, aromatic or non-aromatic heterocyclyl group may be fused), more preferably, a naphthyl ring system.
  • n is selected from 2, 3, 4 are preferred in the context of the present invention, more preferably n is 2.
  • R 5 and R 6 are, each independently, Ci_ 6 alkyl, or together with the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclyl group a, in particular a group chosen among morpholinyl, piperidinyl, and pyrrolidinyl group. More preferably, R 5 and R 6 together form a morpholine-4-yl group.
  • the sigma ligand of formula (I) is selected from:
  • the sigma ligand of formula (I) is 4- ⁇ 2-[5- Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl ⁇ morpholine.
  • This particular compound is designated in the examples of the present invention as compound 63.
  • one aspect of this invention refers to the use of sigma ligand as defined above for the manufacture of a medicament for the prevention and/or treatment of OIH associated to opioid therapy.
  • opioid-induced hyperalgesia or opioid-induced abnormal pain sensitivity is a phenomenon associated with the use of opioids such as morphine, hydrocodone, remifentanyl, oxycodone or methadone. Individuals taking opioids can develop an increasing sensitivity to noxious stimuli, even evolving a painful response to previously non-noxious stimuli (allodynia). Some studies demonstrated that this effect occurs not only after long use of opioids but also after only a single high dose of opioids.
  • tolerance and opioid-induced hyperalgesia both result in a similar need for dose escalation, they are nevertheless caused by two distinct mechanisms. The similar net effect makes the two phenomena difficult to distinguish in a clinical setting.
  • a particular individual's requirement for dose escalation may be due to tolerance (desensitization of antinociceptive mechanisms), opioid-induced hyperalgesia (sensitization of pronociceptive mechanisms), or a combination of both. Identifying the development of hyperalgesia is of great clinical importance since patients receiving opioids to relieve pain may paradoxically experience more pain as a result of treatment.
  • opioid-induced hyperalgesia may worsen the patient's condition by increasing sensitivity to pain while escalating physical dependence. If an individual is taking opioids for a chronic pain condition, and cannot achieve effective pain relief despite increases in dose, they may be experiencing opioid-induced hyperalgesia.
  • the invention is also directed to a combination of at least one sigma ligand as defined above and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of opioid-induced hyperalgesia associated to opioid therapy.
  • Compounds that bind to the opioid receptor within the scope of the present invention include natural opiates, such as morphine, codeine and thebaine; semi-synthetic opiates, derived from the natural opioids, such as hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmorphine, nicomorphine, dipropanoylmorphine, benzylmorphine and ethylmorphine; fully synthetic opioids, such as fentanyl, pethidine, methadone, tramadol and propoxyphene; and endogenous opioid peptides, produced naturally in the body, such as endorphins, enkephalins, dynorphins,
  • the combination according to this invention comprises morphine or its analogues.
  • the combination of the invention may be formulated for its simultaneous separate or sequential administration, with at least a pharmaceutically acceptable carrier, additive, adjuvant or vehicle.
  • a pharmaceutically acceptable carrier, additive, adjuvant or vehicle may be administered: a) As a combination that is being part of the same medicament formulation, the two active compounds being then administered always simultaneously.
  • the sigma ligand is independently administered from the opioid or opiate (i.e in two units) but at the same time.
  • the sigma ligand is administered first, and then the opioid or opiate is separately or sequentially administered. In yet another particular embodiment, the opioid or opiate is administered first, and then the sigma ligand is administered, separately or sequentially, as defined.
  • the auxiliary materials or additives of a pharmaceutical composition according to the present invention i.e.
  • a composition comprising at least one sigma ligand or a composition comprising at least one sigma ligand and at least one opioid or opiate compound can be selected among carriers, excipients, support materials, lubricants, fillers, solvents, diluents, colorants, flavour conditioners such as sugars, antioxidants, binders, adhesives, disintegrants, anti-adherents, glidants and/or agglutinants. In the case of suppositories, this may imply waxes or fatty acid esters or preservatives, emulsifiers and/or carriers for parenteral application.
  • auxiliary materials and/or additives and the amounts to be used will depend on the form of application of the pharmaceutical composition.
  • the pharmaceutical composition in accordance with the invention can be adapted to any form of administration, be it orally or parenterally, for example pulmonar, nasally, rectally and/or intravenously.
  • the formulation in accordance with the invention may be adapted for topical or systemic application, particularly for dermal, transdermal, subcutaneous, intramuscular, intra-articular, intraperitoneal, intravenous, intra-arterial , intravesical , intraosseous, intracavernosal , pul monary, buccal , sublingual, ocular, intravitreal, intranasal, percutaneous, rectal, vaginal, oral, epidural, intrathecal, intraventricular, intracerebral, intracerebroventricular, intracisternal, intraspinal, perispinal, intracranial, delivery via needles or catheters with or without pump devices, or other application routes.
  • Suitable preparations for oral applications are tablets, pills, caplets, gel caps, chewing gums, capsules, granules, drops or syrups.
  • Suitable preparations for parenteral applications are solutions, suspensions, reconstitutable dry preparations, aerosols or sprays.
  • composition of the invention may be formulated as deposits in dissolved form or in patches, for percutaneous application.
  • Skin applications include ointments, gels, creams, lotions, suspensions or emulsions. Suitable form of rectal application is by means of suppositories.
  • composition may be presented in a form suitable for once daily, weekly, or monthly administration.
  • the invention provides a method of treatment of a patient, notably a human, suffering from OIH associated to opioid therapy, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand as defined above.
  • hyperalgesia is suppressed, ameliorated and/or prevented.
  • the sigma ligand can be administered prior to an activity likely to result in hyperalgesia, i.e. opioid administration.
  • the formulation can be administered 30 minutes, 1 hour, 2 hours, 5 hours, 10 hours, 15 hours, 24 hours or even more, such as 1 day, several days, or even a week, two weeks, three weeks, or more prior to the activity likely to result in hyperalgesia, i.e. prior to opioid administration.
  • the sigma ligand can be administered during and/or after the administration of the opioid. In some instances, the sigma ligand is administered 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 30 hours, 36 hours, or more, after the administration of the opioid.
  • the sigma ligand is used in therapeutically effective amounts.
  • the physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of condition being treated. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached.
  • larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally.
  • the compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents.
  • a preferred dosage regime of comprises an administration of a compound according the present invention within a range of 0.01 to 300 mg/kg, more preferably 0.01 to 100 mg/kg, and most preferable 0.01 to 50 mg/kg.
  • Compound 63 can be can be prepared as disclosed in the previous application WO2006/021462. Its hydrochloride can be obtained according the following procedure:
  • Example 2 Modulation on Mechanical Sensitization induced by opioid administration in operated (plantar incision) and naive rats: effect of sigma antagonists
  • the incisional pain model was adapted from Brennan et al. (1996).
  • the induction of anaesthesia in rats was performed with 3% isofluoran for veterinary use, employing an Ohmeda vaporizer and an anaesthesia chamber. Anaesthesia was kept during the surgical operation by a tube which directs the isofluran vapours to the animal's snout. Once the rats were anaesthetised, they were laid down in a prone position and their right hindpaws were cleaned out with alcohol.
  • a skin incision in the hind paw of about 10 mm was made by means of a scalpel, starting about 5 mm from the heel and extending toward the toes. Fascia was located and by means of curve scissors muscle was elevated and a longitudinal incision of about 5 mm was made, thus the muscle origin and insertion remained intact.
  • the skin of the paw was stitched with a suturing stitch with breaded silk (3.0) and the wound was cleaned out with iodinated povidone.
  • opioids morphine, remifentanil, fentanyl or sufentanil
  • sigma antagonists compound 63 or BD-1063
  • the opioid drug is adm inistrated through the intraperitoneal route in three consecutive administrations: at the time of surgery, 15 minutes later and 30 minutes after surgery.
  • the sigma antagonist is administrated only once either 30 minutes before surgery (paradigm 1) or 30 minutes after surgery (paradigm 2).
  • Figure 1 is a schematic representation showing the time course for the two paradigms followed in experimental protocol n° 1.
  • the doses of remifentanil per administration were 0.066 mg/kg each time (0.2 mg/kg total).
  • the doses of morphine were 3.3 mg/kg each time (10 mg/kg in total).
  • the doses of fentanyl per administration were 0.16 mg/kg each time (0.48 mg/kg total).
  • the doses of sufentanil per administration were 0.05 mg/kg each time (0.15 mg/kg total).
  • the doses used for the single administration of sigma antagonist (BD-1063 and compound 63) were 20, 40 and 80 mg/kg.
  • FIG. 12 is a schematic representation showing the time course for experimental protocol n° 2. The long lasting effects of morphine, remifentanil, fentanyl and sufentanil, and the effects of compound n° 63 co-administration on pharmacological effects of the opioids were studied following this protocol.
  • the treatment schedule was as follows: morphine (3.3 mg/kg), remifentanil (0.2 mg/kg), fentanyl (0.16 mg/kg), sufentanil (0.05 mg/kg) or vehicle was injected three times every 15 min starting at the time of plantar incision.
  • the single injection of compound n° 63 was co-administered with the last dose of opioid.
  • all rats received a naloxone injection (2 mg/kg), and the nociceptive threshold was measured 1 , 24 and 48 hours later (see Figures 13-16).
  • the nociceptive threshold was returned to basal 10 days after opioids administrations.
  • the injection of naloxone on day 21 (11 days after the animals had completely recovered their pre-drug nociceptive threshold value) induced a significant decrease in the nociceptive threshold below the basal value.
  • no significant effect of naloxone was observed in vehicle saline-treated rats.
  • naloxone was also unable to precipitate hyperalgesia when it was injected on day 21 in opioid-treated rats that had been co-administrated with 80 mg/kg of compound n° 63 (20 and 40 mg/kg produced an attenuation of naloxone-precipitated hyperalgesia) (see Figures 13-16).
  • opioids morphine or remiphentanyl
  • sigma antagonists compound 63 or BD-1063
  • Naive rats were administrated with 0.3 mg/kg of remifentanil or 10 mg/kg of morphine.
  • the doses of BD-1063 or compound n° 63 were 20, 40 and 80 mg/kg.
  • Opioid administration to naive rats produces, 24 hours after, a significant decrease of the mechanical threshold (that is OIH) as measured with the von Frey filaments application (tactile allodynia for 2 days; figures 7-9). Three days later rats recovered their normal threshold.
  • Compound n° 63 coadministration reduces dose-dependently the enhancement of allodynia induced by remifentanil administration (figure 7).
  • BD-1063 coadministration also reduces the enhancement of allodynia induced by remifentanil (figure 8) and morphine (figure 9) administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

Description

USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA
FIELD OF THE INVENTION
The present invention relates to the use of sigma receptor ligands in the prevention and/or treatment of opioid-induced hyperalgesia (OIH) associated to opioid therapy, including the combination of opioids with a sigma receptor ligand for the treatment and/or prevention of OIH.
BACKGROUND Opioids and opiates are potent analgesics widely used in clinical practice. Opiates refer to alkaloids extracted from poppy pods (Opium Poppy; Papaver Somniferum) and their semi-synthetic counterparts which bind to the opioid receptors. Basically to be called an opiate one has to either be a natural opioid receptor agonist or start the refining process with one of the natural alkaloid molecules. Once chemically altered, such as the process of converting morphine into heroin, the drug is then labeled as a semisynthetic opiate or semi-synthetic opioid - the terms can be used interchangeably. Semi-synthetic opiates (or semi-synthetic opioids) include heroin (diamorphine), oxycodone, hydrocodone, dihydrocodiene, hydromorphone, oxymorphone, buprenorphine and etorphine. In contrast, opioid is a blanket term used for any drug which binds to the opioid receptors. Opioids include all of the opiates as well as any synthesized drug that bind to opioid receptors. Synthetic opioids include methadone, pethidine, fentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, tramadol, tapentadol and loperamide.
Opioid and opiates drugs are classified typically by their binding selectivity in respect of the cellular and differentiated tissue receptors to which specific the drug binds as a ligand. There are 3 well-defined or "classical" types of opioid receptor: mu (μ), delta (δ), and kappa (κ). More recently, cDNA encoding an "orphan" receptor named ORL1 (opioid receptor-like) was identified which has a high degree of homology to the "classical" opioid receptors. All the opioid receptors are G-protein coupled receptors and possess the same general structure: an extracellular N-terminal region, seven transmembrane domains and an intracellular C-terminal tail structure. Pharmacological evidence supporting for subtypes of each receptor and other types of novel, less well- characterised opioid receptors have also been postulated. The well-known opioid analgesics bind to and activate selectively the opioid mu receptors; that is, they act as agonists at mu opioid receptors. The sigma receptor, however, is not regarded as an opioid receptor.
Opioid analgesics are recommended for the management of moderate to severe pain including that which occurs following surgery and trauma and in many patients with cancer. Apart from pain relief, opioid analgesics also produce a range of common well- known side effects (e.g., sedation, emesis, constipation, respiratori depression, dependence).
In addition to the afore-mentioned side-effects, it has been appreciated more recently that opioid analgesics may also activate a pro-nociceptive mechanism resulting in the phenomenon of opioid-induced hyperalgesia (OIH) [also called opioid-induced abnormal pain sensitivity]. OIH is a recognized complication of opioid therapy characterized by enhanced pain sensitivity. Somewhat paradoxically, opioid therapy aiming at alleviating pain may render patients more sensitive to pain and potentially may aggravate their preexisting pain. I n fact, OI H should be considered in the differential when opioid therapy fails. Hence, any apparent decrease in opioid analgesic effectiveness may be due at least in part to the presence of OIH rather than reflecting a worsening of the disease state and/or the development of pharmacological tolerance.
As disclosed in the art (Sandford.M. et al.; Pain Physician 2009; 12:679-684) the existence of OIH is proved by basic science evidence (Mao, J.; Pain 2002; 100:213- 217) and by clinical evidence (Guignard.B. et al.; Anesthesiology 2000; 93:409-417 and Angst, M.S. et al.; Anesthesiology 2006; 104:570-587). Additionally there are neurobiological mechanisms discussed for OI H involving the central glutaminergic system, the spinal dynorphins or the descending facilitation.
OIH is evidenced by individuals taking opioids, which can develop an increasing sensitivity to noxious stimuli (hyperalgesia), even evolving a painful response to previously non-noxious stimuli (allodynia). Increased pain in OIH may result from one or more of the following: pain in the absence of a noxious stimulus (spontaneous pain), increased duration of pain in response to brief stimulation (ongoing pain or hyperpathia), reduced pain threshold (allodynia), increased responsiveness to suprathreshold stimulation (hyperalgesia), spread of pain and hyperalgesia to uninjured tissue (referred pain and secondary hyperalgesia), and abnormal sensations (e.g., dysesthesia, paresthesia).
01 H is a phenomenon often associated with the long term use of opioids, but some studies have demonstrated that this effect can also occur after only a single dose of opioids (E. Celerier et al. , J . Neurosci. 21 , 4074-4080 (2001 )). Thus, OI H occurs following both acute and chronic opioid administration. In this way, OIH is a less recognized side effect of chronic opioid therapy. However, it is becoming more prevalent as the number of patients receiving opioids for chronic pain increases (Trescot.A.M. et al.; Pain Physician 2008; 11 :S12-S16). Increases in pain intensity can occur upon discontinuation of opioid therapy but such an abnormal increased pain sensitivity including hyperalgesia or allodynia can occur also in the absence of overt opioid withdrawal in subjects that have been administered opioid drugs.
The cellular mechanisms underpinning OIH have been proposed to be in common with those of neuropathic pain and analgesic tolerance involving augmented glutamatergic signaling and persistent activation of the /V-methyl-D-aspartate (NMDA)-nitric oxide synthase (NOS)-nitric oxide (NO) signaling cascade.
Another mechanism proposed to underpin opioid-induced excitatory signaling involves stimulation of adenylate cyclase formation via G5-coupled opioid receptors that opposes inhibition of adenylate cyclise formation via Gi/0-coupled opioid receptors to attenuate levels of pain relief (Smith, M.T.; Acute Pain 2008; 10:199-200).
It is known that the combination of opioid analgesics with agents that block excitatory opioid signaling pathways can improve pain relief. Some strategies include combining opioid analgesics with NMDA-receptor antagonists, such as low dose ketamine, and more recently, clinical trials have investigated combinations of ultra-low dose naltrexone (non-selective opioid antagonist) and opioid agonists such as morphine and oxycodone to selective block signaling via G5-coupled opioid receptors (Smith, M.T.; Acute Pain; 2008; 10; 199-200) that are useful in the prevention and/or treatment of opioid-induced hyperalgesia. Sigma receptors are non-opioid receptors of great interest in pharmacology. The sigma binding sites have preferential affinity for the dextrorotatory isomers of certain opiate benzomorphans, such as (+)SKF 10047, (+)cyclazocine, and (+)pentazocine and also for some narcoleptics such as haloperidol. The sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of these pharmacoactive drugs. SKF 10047 has nanomolar affinity for the sigma 1 (σ-1) site, and has micromolar affinity for the sigma 2 (σ-2) site. Haloperidol has similar affinities for both subtypes.
It has been reported that some sigma receptor ligands (i.e., haloperidol) in combination with opioids are capable of modulating the analgesic effect of opioids (both kappa and mu opiods) in models of acute thermal nociceptive tests (i.e., radiant heat tail-flick test) in mice (Mei J and Pasternak GW, Sigma 1 receptor modulation of opioid analgesia in the mouse, J Pharmacol Exp Ther. 2002, 300(3): 1070-1074) and rats (Chien CC and Pasternak GW, Sigma antagonists potentiate opioid analgesia in rats, Neurosci Lett. 1995, 190(2): 137-139). Recently it has been shown that some sigma-1 receptor antagonists potentiate opioid analgesia in models of acute thermal nociceptive pain and that this potentiation of analgesia is not accompanied by potentiation of opioid side effects (i.e., dependence) (WO 2009/130310). However, no information is available regarding inhibition of OIH by sigma-1 receptor ligands.
The treatment of OIH can be time-consuming and, at times, impractical. Weaning patients from high dose opioids usually requires time and patience. While reducing the opioid dose, patients may experience transient increases in pain or exacerbation of pain and the hyperalgesic effect may not be mitigated until a certain critical dose of opioid is reached.
Breaking the cycle of OIH is an attractive course of action for the interventional pain specialist. Thus, there is still a need for substances that could be used as an adjuvant to opioid therapy for the prevention and/or treatment of the associated OIH.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to the use of a sigma ligand as adjuvant in the opioid therapy of pain for the prevention and/or treatment of OIH associated to said opioid therapy. This benefit of the invention is more evident when the sigma ligand is specifically a sigma-1 receptor antagonist, preferably in the form of a (neutral) antagonist, an inverse agonist or a partial antagonist. Therefore, one aspect of the present invention relates to a sigma ligand for use in the prevention and/or treatment of 01 H associated to opioid therapy.
In a preferred embodiment, said sigma ligand has the general formula (I):
Figure imgf000006_0001
(I) wherein
Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyi, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, - C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, - N02, -N=CR8R9, and halogen;
R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyi, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, -C(0)NR8R9, -CH=NR8, -CN, - OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -N02, -N=CR8R9, and halogen; R3 and R4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyi, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, - C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, - N02, -N=CR8R9, and halogen, or together they form an optionally substituted fused ring system; R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, - C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -
N02, -N=CR8R9, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group; n is selected from 1 , 2, 3, 4, 5, 6, 7 and 8; t is 1 ,2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen; or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.
Another aspect of this invention refers to the use of sigma ligand as defined above for the manufacture of a medicament for the prevention and/or treatment of OIH associated to opioid therapy.
Another aspect of the invention is a method of treatment of a patient suffering from OIH associated to opioid therapy, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand as defined above. Another aspect of the invention refers to a combination of at least one sigma ligand as defined above and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of opioid- induced hyperalgesia associated to opioid therapy. These aspects and preferred embodiments thereof are additionally also defined in the claims.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 : Schematic representation of experimental protocol n° 1 (co-administration studies in the perioperative period) showing the time course for the assessment of mechanical sensitization induced by plantar incision. The opioid ligand was administered immediatly after the surgery in three consecutive intraperitoneally injections (every 15 minutes). Paradigm 1 corresponds to a single administration of the sigma receptor ligand immediately before surgery and hence before opioid injection whereas Paradigm 2 corresponds to a single administration of the sigma receptor ligand immediately after the last opioid injection. The experimental protocol n° 1 represents a preventive approach as the sigma ligand is administered in the periooperative period (before-Paradigm 1 or immediately after-Paradigm 2 the opioid administration), long before hyperalgesia develops. Figure 2: It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 1 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
Figure 3: It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
Figures 2 and 3 show that administration of the sigma ligand in the perioperative period inhibits the development of mechanical allodynia when administered both before (Paradigm 1) and after (Paradigm 2) opiod administration. At 40 and 80 mg/kg the sigma ligand (compound n° 63) inhibits allodynia secondary to both surgery and opioid (Remifentanil) use (i.e., OIH). When compound n° 63 is administered at the dose of 20 mg/kg OIH is selectively blocked. Figure 4: It shows the effect of Morphine (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period). Similar to previous figures showing the effect on Remifentanil use, the sigma ligand (compound n° 63) also inhibits allodynia secondary to surgery and OIH when Morphine was used.
Figure 5: It shows the effect of Morphine (opioid receptor agonist) and BD-1063 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (coadministration studies in the perioperative period). The sigma ligand BD-1063 at 80 mg/kg also inhibits the development of OIH when Morphine was used. Figure 6: Schematic representation of experimental protocol n° 3 (co-administration studies in naive rats) showing the time course for the assessment of Mechanical Sensitization (i.e., OIH) induced by opioids.
Figure 7: It shows the effect of Remifentanil (opioid ligand) and compound n° 63 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats). The figure 7 shows the inhibitory effect of compound n° 63 on remifentanil- induced hyperalgesia. The inhibitory effect on OIH is clear at 20 and 40 mg/kg.
Figure 8: It shows the effect of Remifentanil (opioid ligand) and compound BD-1063 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats). Si m ilar to compound n° 63, BD-1063 is able to inhibit OIH (i.e., remifentanil-induced hyperalgesia) when administered at 40 mg/kg.
Figure 9: It shows the effect of Morphine (opioid ligand) and compound BD-1063 (sigma antagonist) according to experimental protocol n° 3 (co-administration studies in naive rats). Not only remifentanil- but also morphine-induced hyperalgesia is inhibited by the sigma ligand BD-1063 when co-administered to naive rats at 40 mg/kg together with the opioid.
Figure 10: It shows the effect of Fentanyl (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period).
Figure 11 : It shows the effect of Sufentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) approached by Paradigm 2 according to experimental protocol n° 1 (co-administration studies in the perioperative period). Figure 12: Schematic representation of experimental protocol n° 2 (OIH precipitated by naloxone).
Figure 13: It shows the effect of Remifentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
Figure 14: It shows the effect of Morphine (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
Figure 15: It shows the effect of Fentanyl (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
Figure 16: It shows the effect of Sufentanil (opioid receptor agonist) and compound n° 63 (sigma antagonist) according to experimental protocol n° 2 (OIH precipitated by naloxone).
DETAILED DESCRIPTION OF THE INVENTION
In the context of the present invention, the following terms have the meaning detailed below.
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of 1 to 12 carbon atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n- pentyl, etc. Alkyl radicals may be optionally substituted by one or more substituents such as aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc. Preferred alkyl radicals have from 1 to 6 carbon atoms. If substituted by aryl, it corresponds to an "Arylalkyl" radical, such as benzyl or phenethyl. If substituted by heterocyclyl, it corresponds to a "Heterocyclylalkyl" radical.
"Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting of 2 to 12 carbon atoms, containing at least one unsaturation, and which is attached to the rest of the molecule by a single bond. Alkenill radicals may be optionally substituted by one or more substituents such as aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc. Preferred alkenyl radicals have from 2 to 6 carbon atoms.
"Cycloalkyl" refers to a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated, and which consist solely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.
"Aryl" refers to single and multiple aromatic ring radicals, including multiple ring radicals that contain separate and/or fused aryl groups. Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms, such as phenyl, naphthyl, indenyl, fenanthryl or anthracyl radical. The aryl radical may be optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl, alkoxycarbonyl, etc. "Heterocyclyl" refers to a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. It may be aromatic or not aromatic. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated or aromatic. Examples of such heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran, coumarine, morpholine; pyrrole, pyrazole, oxazole, isoxazole, triazole, imidazole, etc.
"Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, e. g. , methoxy, ethoxy, propoxy, etc.
"Am i no" refers to a rad ical of the form u la -NH2, -NHRa or -NRaRb, optionally quaternized, e.g. , methylamino, ethylamino, dimethylamino, diethylamino, propylamino, etc.
"Halogen", "halo" or "hal" refers to bromo, chloro, iodo or fluoro. References herein to substituted groups in the compounds of the present invention refer to the specified moiety that may be substituted at one or more available positions by one or more suitable groups, e. g. , halogen such as fluoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; azido; alkanoyl such as a Ci_6 alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1 -3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocylic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
The term "salt" must be understood as any form of an active compound used in accordance with this invention in which said compound is in ionic form or is charged and coupled to a counter-ion (a cation or anion) or is in solution. This definition also includes quaternary ammonium salts and complexes of the active molecule with other molecules and ions, particularly, complexes formed via ionic interactions. The definition includes in particular physiologically acceptable salts; this term must be understood as equivalent to "pharmacologically acceptable salts" or "pharmaceutically acceptable salts".
The term "pharmaceutically acceptable salts" in the context of this invention means any salt that is tolerated physiologically (normally meaning that it is not toxic, particularly, as a result of the counter-ion) when used in an appropriate manner for a treatment, applied or used, particularly, in humans and/or mammals. These physiologically acceptable salts may be formed with cations or bases and, in the context of this invention, are understood to be salts formed by at least one compound used in accordance with the invention -normally an acid (deprotonated)- such as an anion and at least one physiologically tolerated cation, preferably inorganic, particularly when used on humans and/or mammals. Salts with alkali and alkali earth metals are preferred particularly, as well as those formed with ammonium cations (NH4 +). Preferred salts are those formed with (mono) or (di)sodium, (mono) or (di)potassium, magnesium or calcium. These physiologically acceptable salts may also be formed with anions or acids and, in the context of this invention, are understood as being salts formed by at least one compound used in accordance with the invention - normally protonated, for example in nitrogen - such as a cation and at least one physiologically tolerated anion, particularly when used on humans and/or mammals. This definition specifically includes in the context of this invention a salt formed by a physiologically tolerated acid, i.e. salts of a specific active compound with physiologically tolerated organic or inorganic acids - particularly when used on humans and/or mammals. Examples of this type of salts are those formed with: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
The term "solvate" in accordance with this invention should be understood as meaning any form of the active compound in accordance with the invention in which said compound is bonded by a non-covalent bond to another molecule (normally a polar solvent), including especially hydrates and alcoholates, like for example, methanolate. A preferred solvate is the hydrate.
Any compound that is a prodrug of a sigma ligand, in particular a prodrug of a compound of formula (I) is also within the scope of the invention. The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Examples of prodrugs include, but are not limited to, derivatives and metabolites of the compounds of formula I that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Preferably, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger "Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001 , Wiley), "Design and Applications of Prodrugs" (H. Bundgaard ed., 1985, Harwood Academic Publishers) and Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery" Taylor & Francis (April 2002).
Any compound referred to herein is intended to represent such specific compound as well as certain variations or forms. In particular, compounds referred to herein may have asymmetric centres and therefore exist in different enantiomeric or diastereomeric forms. Thus, any given compound referred to herein is intended to represent any one of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, and mixtures thereof. Likewise, stereoisomerism or geometric isomerism about the double bond is also possible, therefore in some cases the molecule could exist as (E)-isomer or (Z)-isomer (trans and cis isomers). If the molecule contains several double bonds, each double bond will have its own stereoisomerism, that could be the same as, or different to, the stereoisomerism of the other double bonds of the molecule. Furthermore, compounds referred to herein may exist as atropisomers. All the stereoisomers including enantiomers, diastereoisomers, geometric isomers and atropisomers of the compounds referred to herein , and mixtures thereof, are considered within the scope of the present invention.
Furthermore, any compound referred to herein may exist as tautomers. Specifically, the term tautomer refers to one of two or more structural isomers of a compound that exist in equilibrium and are readily converted from one isomeric form to another. Common tautomeric pairs are amine-imine, amide-imidic acid, keto-enol, lactam-lactim, etc.
Unless otherwise stated, the compounds of the invention are also meant to include isotopically-labelled forms i.e. compounds which differ only in the presence of one or more isotopically-enriched atoms. For example, compounds having the present structures except for the replacement of at least one hydrogen atom by a deuterium or tritium, or the replacement of at least one carbon by 13C- or 14C-enriched carbon, or the replacement of at least one nitrogen by 15N-enriched nitrogen are within the scope of this invention.
The sigma ligands, in particular the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts, solvates or prodrugs.
As noted previously, the term "pharmaceutically acceptable salts, solvates, prodrugs" refers to any salt, solvate, or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound as described herein. However, it will be appreciated that non-pharmaceutically acceptable salts, solvates and prodrugs also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts, solvates and prodrugs. The preparation of salts, solvates and prodrugs can be carried out by methods known in the art.
As used herein, the terms "treat", "treating" and "treatment" include the eradication, removal, reversion, alleviation, modification, or control of opioid-induced hyperalgesia (OIH).
As used herein, the terms "prevention", "preventing", "preventive" "prevent" and prophylaxis refer to the capacity of a therapeutic to avoid, minimize or difficult the onset or development of a disease or condition before its onset, in this case opioid-induced hyperalgesia (OIH).
Therefore, by "treating" or "treatment" and "preventing" or "prevention", as a whole, is meant at least a suppression or an amelioration of the symptoms associated with the condition afflicting the subject, where suppression and amelioration are used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g., symptom associated with the condition being treated, such as OIH. As such, the method of the present invention also includes situations where the condition is completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the subject no longer experiences the condition. As such , the present method includes both preventing and managing acute and chronic OIH.
As used herein, the terms "sigma ligand" or "sigma receptor ligand" refer to any compound binding to the sigma receptor. As stated previously, the sigma ligand is preferebly a sigma receptor antagonist in the form of a (neutral) antagonist, an inverse agonist or a partial antagonist.
An "agonist" is defined as a compound that binds to a receptor and has an intrinsic effect, and thus, increases the basal activity of a receptor when it contacts the receptor. An "antagonist" is defined as a compound that competes with an agonist or inverse agonist for binding to a receptor, thereby blocking the action of an agonist or inverse agonist on the receptor. However, an antagonist (also known as a "neutral" antagonist) has no effect on constitutive receptor activity. Antagonists mediate their effects by binding to the active site or to allosteric sites on receptors, or they may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity. Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist-receptor complex, which, in turn, depends on the nature of antagonist receptor binding. A "partial antagonist" is defined as a compound that binds to the receptor and generates an antagonist response; however, a partial antagonist does not generate the full antagonist response. Partial antagonists are weak antagonists, thereby blocking partially the action of an agonist or inverse agonist on the receptor.
An "inverse agonist" is defined as a compound that produces an effect opposite to that of the agonist by occupying the same receptor and, thus, decreases the basal activity of a receptor (i.e., signalling mediated by the receptor). Such compounds are also known as negative antagonists. An inverse agonist is a ligand for a receptor that causes the receptor to adopt an inactive state relative to a basal state occurring in the absence of any ligand. Thus, while an antagonist can inhibit the activity of an agonist, an inverse agonist is a ligand that can alter the conformation of the receptor in the absence of an agonist.
"The sigma receptor/s" as used in this application is/are well known and defined using the following citation: "this binding site represents a typical protein different from opioid, NMDA, dopaminergic, and other known neurotransmitter or hormone receptor families" (G. Ronsisvalle et al. Pure Appl. Chem. 73, 1499-1509 (2001)). Pharmacological data based on ligand binding studies, anatomical distribution and biochemical features distinguish at least two subtypes of σ receptors (R. Quiron et al. , Trends Pharmacol. Sci. 13, 85-86 (1992); M.L.Leitner, Eur. J. Pharmacol. 259, 65-69 (1994); S.B. Hellewell and W. D. Bowen; Brain Res. 527, 244-253 (1990)) (G. Ronsisvalle et al. Pure Appl. Chem. 73, 1499-1509 (2001)). The protein sequences of the sigma receptors (Sigma 1 (σ1) and Sigma 2 (σ2)) are known in the art (e.g. Prasad, P.D. et al., J. Neurochem. 70 (2), 443-451 (1998)). They show a very high affinity to various analgesics (e.g. pentazocine). "Com pound/s binding to the sigma receptor" or "sigma ligand" as used in this application is/are defined as a compound having an IC50 value of ≤ 5000 nM, more preferably ≤ 1 000 nM, more preferably ≤ 500 nM on the sigma receptor. M ore preferably, the IC50 value is≤ 250 nM. More preferably, the IC50 value is≤ 100 nM. Most preferably, the IC50 value is≤ 50 nM. The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. The IC50 is the concentration of competing ligand which displaces 50% of the specific binding of the radioligand. Additionally, the wording "Compound/s binding to the sigma receptor", as used in the present application is defined as having at least >50% displacement using 10 nM radioligand specific for the sigma receptor (e.g. preferably [3H]-(+) pentazocine) whereby the sigma receptor may be any sigma receptor subtype. Preferably, said compounds bind to the sigma-1 receptor subtype.
Compounds binding to the sigma receptor, generally also referred to as sigma ligands, are well known in the art. Many of them are encompassed by the "Compound/s binding to the sigma receptor" definition above. Although there are many known uses for sigma ligands, such as antipsychotic drugs, anxiolytics, antidepressants, stroke treatment, antiepileptic drugs and many other indications, including anti-migraine and general pain, there is no mention in the art of these compounds as useful for the treatment of opioid-induced hyperalgesia (OIH) associated to opioid therapy.
Table 1 lists some sigma ligands known in the art (i.e. having an IC50≤ 5000 nM). Some of these compounds may bind to the sigma-1 and/or to the sigma-2 receptor. These sigma ligands also include their respective salts, bases, and acids.
Table 1
(-)-Cyanopindolol hemifumarate Cutamesine hydrochloride
(-)-(1 R,2S)-cis-N-[2-(3,4- Cyclobenzaprine HCI
Dichlorophenyl)ethyl]-2- pyrrolidinocyclohexylamine
(-)-1 -[1 -(3-Chlorophenyl)pyrrolidin-2-ylmethyl]- Cycloheximide
4-(2-phenylethyl)piperazine (-)-Sparteine sulfate pentahydrate Cyproheptadine HCI
(+)-Himbacine Darrow Red HCI
(±)-1 -Cyclohexyl-4-[3-(5-methoxy-1 ,2,3,4- Demecarium Bromide tetrahydronaphthalen-1 -yl)propyl]piperazine
(1 S,5R)-3-[2-(2-Adamantyl)ethyl]-1 ,8,8- Denatonium Benzoate trimethyl-3-azabicyclo[3.2.1 ]octane
hydrochloride
(2-Dibutylamino-Ethyl)-Carbamic Acid 2-(4- Deptropine Citrate
Benzofuran-2-Ylmethyl-Piperazin-1 -YI)-Ethyl
Ester
(4-[1 ,2,3]Thiadiazol-4-YI-Benzyl)-Carbamic Desloratadine
Acid 1 -(3-Methoxy-2-Nitro-Benzyl)-Piperidin-3- Ylmethyl Ester
(4aalpha,8aalpha)-6-(4-Fluorophenyl)-2-(4- Dexbrompheniramine Maleate pyridylmethyl)-6- hydroxydecahydroisoquinoline; (4a,8a-cis)-6-
(4-Fluorophenyl)-2-(pyridin-4- ylmethyl)perhydroisoquinolin-6-ol
(4aalpha,8abeta)-2-Benzyl-6-(4-fluorophenyl)- Dexchlorpheniramine Maleate 6-hydroxydecahydroisoquinoline
(6aR,9R)-5-Bromo-7-methyl-N-(2-propynyl)- Dexfenfluramine HCI
4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-
9-carboxamide
(S)-(-)-N-(2-Amino-3-phenylpropyl)-2-(3,4- Dicyclomine HCI dichlorophenyl)-N-methylacetamide
hydrochloride
(S)-Methamphetamine HCI Diethylpropion HCI
[1 -(9-Ethyl-9H-Carbazol-3-Ylmethyl)- Dimethisoquin HCI
Pyrrolidin-3-YI]-Carbamic Acid 1 -(3- Benzyloxy-4-Methoxy-Benzyl)-Piperidin-3- Ylmethyl Ester [1 -(9-Ethyl-9H-Carbazol-3-Ylmethyl)- Dimetindene Maleate Pyrrolidin-3-YI]-Carbamic Acid 2-(Tert- Butoxycarbonyl-Naphthalen-1 -Ylmethyl- Amino)-Ethyl Ester
[4-(4-Ethyl-3,5-Dimethyl-Pyrazol-1 -YI)- Diphemanil Methylsulfate
Phenyl]-[4-(3-Phenyl-Allyl)-Piperazin-1 -YI]-
Methanone
1 -(1 ,2-Diphenylethyl)Piperidine Maleate, (+/-) Diphenidol HCI
1 -(1 ,4-Ethano-1 ,2,3,4-tetrahydro-2- Diphenoxylate HCI naphthylmethyl)-4-methylpiperazine hydrate;
1 -(Benzobicyclo[2.2.2]octen-2-ylmethyl)-4- methylpiperazine hydrate
1 -(1 -Adamantyl)-2-[4-(2H-naphtho[1 ,8- Diphenylpyraline HCI cd]isothiazol-2-ylmethyl)piperidin-1 - yl]ethanone S,S-dioxide hydrochloride
1 -(1 -Naphthyl)Piperazine HCI Dipropyldopamine HBr
1 -(2-Benzyloxyethyl)-4-(3- Doxepin HCI phenylpropyl)piperazine dihydrochloride
1 -(2-Phenylethyl)piperidine oxalate Dyclonine HCI
1 -(3-Chlorophenyl)Piperazine HCI Ebastine
1 -(3-Chlorothien-2-yl)-2-[4-(4- Econazole Nitrate fluorobenzyl)piperidin-1 -yl]ethanol
1 -(4-Bromo-Benzenesulfonyl)-4-(2-Tert- Epinastine HCI Butylsulfanyl-Benzyl)-Piperazine
1 -(4-Chloro-3-hydroxyphenyl)-2-[4-(4- Ethaverine HCI fluorobenzyl)piperidin-1 -yl]ethanol
1 -(4-Chlorophenyl)-3-(hexahydroazepin-1 - Ethopropazine HCI ylmethyl)pyrrolidin-2-one
1 -(4-Chlorophenyl)-3(R)-[4-(2-methoxyethyl)- Eticlopride HCI, S(-)- 1 -piperazinylmethyl]pyrrolidin-2-one (-)-D- tartrate
1 -(4-Chlorophenyl)-3(R)-[4-(2- Etofenamate
methoxyethyl)piperazin-1 -ylmethyl]pyrrolidin- 2-one dihydrochloride
1 '-(4-Fluorobenzyl)-1 ,3-dihydrospiro[2- Etonitazenyl Isothiocyanate benzofuran-1 ,4'-piperidine]
1 -(4-Fluorophenyl)-4-[4-(5-fluoro-2- Femoxetine HCI
pyrimidinyl)-1 -piperazinyl]butan-1 -ol
hydrochloride
1 -(4-Fluorophenyl)-4-[4-(5-fluoropyrimidin-2- Fenfluramine HCI
yl)piperazin-1 -yl]butan-1 -ol; 1 -[4-(4- Fluorophenyl)-4-hydroxybutyl]-4-(5- fluoropyrimidin-2-yl)piperazine
1 '-(4-Phenylbutyl)spiro[1 ,3- Fenticonazole Nitrate dihydroisobenzofuran-1 ,4'-piperidine]
1 -(Cyclobutylmethyl)-2-[3-phenyl-2(E)- Fipexide HCI
propenyl]pyrrolidine hydrochloride
1 -(Cyclohexylmethyl)-3'-methoxy-5'-phenyl- Flavoxate HCI
4',5'-dihydro-3'H-spiro[piperidine-4,1 '- pyrano[4,3-c]pyrazole]
1 -(Cyclopropylmethyl)-4-[2-(4-fluorophenyl)-2- Flunarizine diHCI
oxoethyl]piperidine hydrobromide
1 ,4-Bis[spiro[isobenzofuran-1 (3Η),4'- Fluoxetine Related Compound B piperidin]-1 '-yl]butane
1 -[(1 R,3R)-2,2-Dimethyl-3-(2- Fluperlapine
phenoxyethyl)cyclobutylmethyl]piperidine
1 -[2-(3,4-Dichlorophenyl)ethyl]-3-(pyrrolidin-1 - Fluphenazine Decanoate DiHCI yl)piperidine
1 -[2-(3,4-Dichlorophenyl)ethyl]-4-(3- Fluphenazine Enanthate DiHCI phenylpropyl)piperazine 1 -[2-(3,4-Dichlorophenyl)ethyl]-4- Fluphenazine HCI
methylpiperazine
1 -[2-(4-Fluorophenyl)ethyl]-4,4- Fluphenazine N-Mustard DiHCI dimethylhexahydroazepine hydrochloride
1 -[2-[1 -(3,4-Dichlorophenyl)-5-methyl-1 H- Flurazepam Related Compound C 1 ,2,4-triazol-3-ylsulfanyl]ethyl]piperidine
oxalate
1 -[2-Benzyloxy-1 (R)-phenylethyl]-4- Fluspirilene
cyclohexylpiperazine dihydrochloride
1 -[3-(2-Oxo-3-phenylimidazolin-1 - GBR 12783 DiHCI
yl)propyl]spiro[piperidine-4,1 '(3H)- isobenzofuran] hydrochloride; 1 -Phenyl-3-[3- [spiro[piperidine-4,1 '(3H)-isobenzofuran]-1 - yl]propyl]imidazolin-2-one hydrochloride
1 -[3-(3,4-Dimethoxyphenyl)propyl]-4-(4- GBR 12909 DiHCI
phenylbutyl)perhydro-1 ,4-diazepine
dihydrochloride
1 -[3-(4-Chlorophenoxy)propyl]-4- GBR 13069 DiHCI
methylpiperidine hydrochloride
1 -[3-(4-Phenyl-2H-1 ,2,3-triazol-2- GBR-12935 DiHCI
yl)propyl]piperidine
1 -[4-(6-Methoxynaphthalen-1 -yl)butyl]-3,3- GR 89696 Fumarate
dimethylpiperidine hydrochloride
1 -[4-[2-[1 -(3,4-Dichlorophenyl)-1 H-pyrazol-3- Guanabenz Acetate
yloxy]ethyl]piperazin-1 -yl]ethanone oxalate
1 1 -[5-(4-Fluorophenyl)-5-oxopentyl]- Guanadrel Sulfate
5,6,7,8,9,10-hexahydro-7, 10- iminocyclohept[b]indole
1 -Benzyl-3beta-[3- Halofantrine HCI
(cyclopropylmethoxy)propyl]-
2alpha,3alpha,4beta-trimethylpiperidine 1 -Benzyl-3-methoxy-3',4'- HEAT HCI
dihydrospiro(piperidine-4,1 '-thieno[3,2- c]pyrane)
1 '-Benzyl-3-methoxy-4-phenyl-3,4- Hexylcaine HCI dihydrospiro[furo[3,4-c]pyrazole-1 ,4'- piperidine]
1 -Benzyl-4-(4-fluorophenoxymethyl)piperidine Hycanthone
1 -Benzyl-4-[2-(4-fluorophenyl)-2- Hydroxychloroquine Sulfate oxoethyl]piperidine maleate
1 -Benzyl-4-[3-phenyl-2(E)- IBZM, S(-)- propenyloxymethyl]piperidine hydrochloride
1 -Benzyl-4-[4-(4-fluorophenyl)-3-cyclohexen- ICI-199,441 HCI
1 -yl]piperazine dihydrochloride hemihydrate
1 '-Benzylspiro[1 ,2,3,4-tetrahydronaphthalene- Ifenprodil Tartrate
1 ,4'-piperidine]
1 '-Benzylspiro[indane-1 ,4'-piperidine] Indatraline HCI
1 '-Butyl-3-Methoxy-4-phenyl-3,4- lofetamine HCI dihydrospiro[furo[3,4-c]pyrazole-1 ,4'- piperidine]
1 -Cyclohexyl-4-(3-phenoxypropyl)piperazine Isamoltane Hemifumarate dihydrochloride
1 -Hydroxy-1 '-(2-phenylethyl)spiro[1 ,2,3,4- Isoxsuprine HCI tetrahydronaphthalene-2,4'-piperidine]
hydrochloride
1 -Methyl-4-[2-(4-phenylpiperidin-1 -yl)ethyl]- Ketotifen Fumarate Salt 4,5,6,7-tetrahydro-1 H-indazole oxalate
1 -Phenyl-3-(1 -propyl-1 ,2,5,6- L-693,403 Maleate tetrahydropyridin-3-yl)-1 -propanone oxime
oxalate 1 -Phenyl-4-(pyrrolidin-1 -ylmethyl)-1 ,4,6,7- L-741 ,626 tetrahydropyrano[4,3-c]pyrazole
2-(2-{[1 -(3-Chloro-Benzyl)-Pyrrolidin-3-YI]- L-741 ,742 HCI Methyl-Carbamoyl}-2-Methyl-Propyl)-4,6- Dimethyl-Benzoic Acid
2-(3,4-Dichlorophenyl)-N-methyl-N-[2- L-745,870 TriHCI
(1 ,2alpha,3alpha,4beta-tetramethylpiperidin-
3beta-yl)ethyl]acetamide
2-(Cyclohexylmethylaminomethyl)-8-methoxy- Levetimide HCI, R(-) 3, 4-dihydro-2H-1 -benzopyran hydrochloride
2(S)-[(3aS,6aR)-5-Butyl-4-oxo-1 ,2,3,3a,4,6a- Levobunolol HCI hexahydrocyclopenta[c]pyrrol-2-yl]propionic
acid ethyl ester
2-[2-[5-Methyl-1 -(2-naphthyl)-1 H-pyrazol-3- Lidoflazine yloxy]ethylamino]ethanol hydrochloride
2-[2-[N-(Cyclobutylmethyl)-N- Lobeline HCI methylamino]ethyl]-1 ,2,3,4- tetrahydronaphthalen-2-one
2-[3-[4-(2-Methoxyphenyl)piperazin-1 - lomerizine diHCI yl]propoxy]-9H-carbazole
2-[4-(4-Methoxybenzyl)piperazin-1 -ylmethyl]- Loxapine Succinate 4H-1 -benzopyran-4-one
2-[N-[2-(3,4-Dichlorophenyl)ethyl]-N- LY-53,857 Maleate methylaminomethyl]-1 -ethylpyrrolidine
2-Benzyl-3,4,8-trimethyl-2- Maprotiline HCI azabicyclo[2.2.2]octane-6-carboxylic acid
ethyl ester
2-Butyl-2,3,4,4a,9,9a-hexahydro-1 H- Mazindol indeno[2,1 -c]pyridine
2-Chloro-1 1 -(4- MDL 12.330A HCI Methylpiperazino)Dibenz[B,F]Oxepin Maleate
3-(1 -Benzyl-2r,3c,4t-trimethylpiperidin-3t- Mebhydroline 1 ,5-naphthalendisulfonate Salt yl)propionic acid ethyl ester hydrochloride
3-(3-Chloro-4-cyclohexylphenyl)-1 - Meclizine HCI
(hexahydroazepin-1 -yl)-1 (Z)-propene
hydrochloride; 1 -[3-(3-Chloro-4- cyclohexylphenyl)-2(Z)- propenyl]hexahydroazepine hydrochloride
3-(4-Methylphenyl)-5-(1 -propyl-1 ,2,5,6- Mefloquine HCI
tetrahydropyridin-3-yl)isoxazole oxalate
3-(N-Benzyl-N-methylamino)-1 -(4- Meprylcaine HCI
nitrophenyl)piperidine
3,3'-Diethylthiacarbocyanine Iodide Mesoridazine Besylate
3-[1 -(Benzocyclobutan-1 -ylmethyl)piperidin-4- Metaphit Methanesulfonate
yl]-6-fluoro-1 ,2-benzisoxazole
3-[2-(2-Adamantyl)ethyl]-3- Metaphit
azabicyclo[3.2.2]nonane
3-[3-(4-Methylphenyl)isoxazol-5-yl]-1 -propyl- Methantheline Bromide
1 ,2,5,6-tetrahydropyridine
3a,6-Epoxy-2-[2-(4-fluorophenyl)ethyl]- Methdilazine
2,3,3a,6,7,7a-hexahydro-1 H-isoindole
3a,6-Epoxy-2-[2-(4- Methiothepin Mesylate
fluorophenyl)ethyl]perhydroisoindole
3-Mercapto-2-Methylpropanoic Acid 1 ,2- Methixene HCI
Diphenylethylamine Salt
3-Phenyl-1 -(1 -propyl-1 ,2,5,6-tetrahydro-3- Methylene Violet 3Rax HCI
pyridyl)-1 -propanone oxime
monohydrochloride
3-Quinuclidinyl Benzilate Metipranolol 3-Tropanyl-3,5-Dichlorobenzoate Mianserin HCI
3-Tropanyl-lndole-3-Carboxylate HCI Miconazole
4-(1 H-lndol-4-YI)-Piperazine-1 -Carboxylic ML-9 HCI
Acid 2-(5-Bromo-2-Ethoxy-Phenylamino)- Cyclohexylmethyl Ester
4-(2-Tert-Butylsulfanyl-Benzyl)-Piperazine-1 - Morantel Hydrogen L-Tartrate
Carboxylic Acid 2-Thiophen-2-YI-Ethyl Ester
4-(3,5-Dimethoxy-Phenyl)-Piperazine-1 - MR 16728 HCI
Carboxylic Acid 1 -(2-Fluoro-Benzyl)-Piperidin- 2-Ylmethyl Ester
4-(3-Nitro-5-Sulfamoyl-Thiophen-2-YI)- MT-210
Piperazine-1 -Carboxylic Acid 1 -(2-Fluoro-5- Methoxy-Benzyl)-Piperidin-3-Ylmethyl Ester
4-(4-Benzylpiperazin-1 -ylmethyl)-7-methoxy- N-(2-Adamantyl)-N-[2-(2-adamantyl)ethyl]-N- 2H-1 -benzopyran-2-one methylamine hydrochloride
4-(4-Bromophenyl)-5-[2- N-[1 -(2-lndanyl)piperidin-4-yl]-N-
(dihexylamino)ethyl]thiazol-2-amine methylcarbamic acid isobutyl ester fumarate dihydrochloride
4-(4-Fluorobenzoyl)-1 -(4- N-[1 -[4-Methoxy-3-(2-phenylethoxy)benzyl]-4- Phenylbutyl)Piperidine Oxalate methylpentyl]-N-propylamine
4-(4-Methylphenyl)-1 -(3-morpholinopropyl)- N-[2-(3,4-Dichlorophenyl)ethyl]-N-ethyl-N-[2- 1 ,2,3,6-tetrahydropyridine (1 -pyrrolidinyl)ethyl]amine
4-(5-Trifluoromethyl-Pyridin-2-YI)-Piperazine- N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-N- 1 -Carboxylic Acid Pent-2-Ynyl Ester (2-pyrrolidinoethyl)amine dihydrobromide
4-(Dimethylamino)-1 -phenylcyclohexanol N-[4-[4-(Diethylamino)piperidin-1 - yl]phenyl]methanesulfonamide
4,7-Epoxy-2-[2-(4-fluorophenyl)ethyl]- N1 -(1 -Adamantyl)-N2-(2- 2,3,3a,4,7,7a-hexahydro-1 H-isoindole methylphenyl)acetamidine
4-[1 -(3-[18F]fluoropropyl)piperidin-4- N1 -[2-(3,4-Dichlorophenyl)ethyl]-N1 ,N2,N2- ylmethoxy]benzonitrile trimethyl-1 ,2-ethanediamine
4-[1 -(4-Chlorobenzyl)-4-(benzylpiperidin-4-yl]- Nafronyl Oxalate Salt
2-hydroxy-4-oxobut-2-enoic acid
4-[1 -(4-Fluorophenyl)-1 -hydroxymethyl]-1 -[3- Naftifine
(4-fluorophenoxy)propyl]piperidine
4-[2-(Dipropylamino)ethyl]-2-(2- Naftopidil diHCI
phenylethoxy)anisole hydrochloride
4-[2-(Dipropylamino)ethyl]-5,8- Naltriben Mesylate
dimethylcarbazole hydrochloride
4-[2-[1 -(3,4-Dichlorophenyl)-5-methyl-1 H- NE-100
pyrazol-3-yloxy]ethyl]morpholine
4-[2-[1 -(Cyclopropylmethyl)piperidin-4- Nefazodone
yl]acetyl]benzonitrile fumarate
4-[4-(N-Benzyl-N-methylamino)piperidin-1 - N-Ethyl-N-[2-(1 -piperidinyl)ethyl]-N-[2-[4- yl]benzonitrile (trifluoromethoxy)phenyl]ethyl]amine
4-[N-[2-[N'-(4-Fluorobenzyl)-N'- Nicergoline
methylamino]ethyl]-N-methylamino]-1 -(4- fluorophenyl)-1 -butanone dihydrochloride
4-Benzyl-1 -[4-(4-fluorophenyl)-4- Niguldipine HCI, (+/-)- hydroxybutyl]piperidine hydrochloride
4-Bromo-N-[1 -(9-Ethyl-9H-Carbazol-3- Nisoxetine HCI
Ylmethyl)-Pyrrolidin-3-YI]-2-Trifluoromethoxy-
Benzenesulfonamide
4'-Chloro-3-Alpha-(Diphenylmethoxy)Tropane NP-07
HCI
4-Furan-2-Ylmethyl-Piperazine-1 -Carboxylic Nylidrin HCI
Acid 2-{4-[3-(2-Trifluoromethyl-Phenothiazin- 10-YI)-Propyl]-Piperazin-1 -Yl}-Ethyl Ester
4-Methoxy-1 -[2-(4-phenylpiperazin-1 -yl)ethyl]- Octoclothepin Maleate, (±)- 6H-dibenzo[b,d]pyran hydrochloride
4- Methoxy-N-[1 -(7-Methoxy-Benzo[1 ,3]Dioxol- Oxamniquine
5- Ylmethyl)-Pyrrolidin-3-YI]- Benzenesulfonamide
4-Phenyl-1 -(3-phenylpropyl)-4-(pyrrolidin-1 - Oxamniquine Related Compound A ylcarbonyl)piperidine
5-(2-Pyrrolidinoethyl)-4-(2,4,6- Oxamniquine Related Compound B trimethoxyphenyl)thiazole-2-amine
dihydrochloride
5-(N-Ethyl-N-lsopropyl)-Amiloride Oxatomide
6-[1 -Hydroxy-2-[4-(2-phenylethyl)piperidin-1 - Oxiconazole Nitrate
yl]ethyl]-1 ,2,3,4-tetrahydroquinolin-2-one
6-[2-(4-Benzylpiperidin-1 -yl)ethyl]-3- Panamesine hydrochloride methylbenzothiazol-2(3H)-one
6-[2-[4-(2-Phenylethyl)piperidin-1 -yl]ethyl]- Panaxatriol
1 ,2,3,4-tetrahydroquinolin-2-one
6-[3-(Morpholin-4-yl)propyl]benzothiazol- PAPP
2(3H)-one
6-[6-(4-Hydroxypiperidin-1 -yl)hexyloxy]-3- Paroxetine
methyl-2-phenyl-4H-1 -benzopyran-4-one
7-(4-Methoxyphenyl)-4-[4-(4- Paxilline
pyridyl)butyl]hexahydro-1 ,4-thiazepine
7-[3-[4-(4-Fluorobenzoyl)piperidin-1 - p-Chlorobenzhydrylpiperazine yl]propoxy]-4H-1 -benzopyran-4-one
hydrochloride
9-[4-({[4'-(trifluoromethyl)-1 ,1 '-biphenyl-2- Penbutolol Sulfate
yl]carbonyl}amino)piperidin-1 -yl]-N-(2,2,2- trifluoroethyl)-9H-fluorene-9-carboxamide
9-Hydroxy-2,3,6,7,7a,8,12b,12c-octahydro- Pentamidine Isethionate 1 H,5H-naphtho[1 ,2,3-ij]quinolizine
Acetophenazine Maleate Pergolide Methanesulfonate
Acrinol Perospirone
Ajmaline Phenamil Methanesulfonate
Alaproclate HCI Phenosafranin HCI
Aloe-Emodin Piboserod
Alprenolol D-Tartrate Salt Hydrate Pimozide
Alprenolol HCI Pinacyanol Chloride
AMI-193 Pindobind, (+/-)-
Aminobenztropine Piperacetazine
Amiodarone HCI Piperidolate HCI
Amodiaquine HCI Pirenperone
Amorolfine HCI PPHT HCI, (±)-
Amoxapine Prenylamine Lactate Salt
AN2/AVex-73; AE-37; ANAVEX 2-73; N-(2,2- Pridinol Methanesulfonate Salt
Diphenyltetrahydrofuran-3-ylmethyl)-N,N- dimethylamine
Anavex 1 -41 ; AE-14; N-(5,5- Procyclidine HCI
Diphenyltetrahydrofuran-3-ylmethyl)-N,N- dimethylamine hydrochloride
Anavex 19-144; AE-37met; AN19/AVex-144 Proflavine Hemisulfate Salt
Anavex 7-1037 Propafenone HCI
Anisotropine Methylbromide Proparacaine HCI
Anpirtoline Propiomazine
ARC 239 DiHCI Protokylol Auramine O HCI Protriptyline HCI
Azaperone Pyrilamine Maleate
Azatadine Maleate Pyrimethamine
Azelastine HCI Pyrrolidine-1 ,2-Dicarboxylic Acid 1 -[1 -(4- Allyloxy-Benzyl)-Piperidin-2-Ylmethyl] Ester 2- Benzyl Ester
Bamethan sulfate Pyrvinium Pamoate
BD 1008 DiHBr Quetiapine Fumarate
BD-1063 Quinacrine HCI
Benextramine TetraHCI Quinaldine Red
Benfluorex HCI Quipazine Dimaleate
Benidipine HCI Quipazine, 6-Nitro-, Maleate
Benoxathian HCI Raloxifene
Benproperine Phosphate Rimantadine HCI
Benzododecinium bromide Rimcazole hydrochloride
Benzphetamine HCI Risperidone
Benztropine Mesylate Ritanserin
Bephenium Hydroxynaphthoate Ritodrine HCI
Bepridil HCI RS 23597-190 HCI
Berberine chloride RS 67333 HCI
Betaxolol HCI RS 67506 HCI
Bifemelane Safranin O HCI
BMY 7378 DiHCI Salmeterol
Bopindolol Malonate SB203186 BP 554 Maleate SCH-23390 HCI, R(+)-
Bromhexine HCI Sertaconazole Nitrate
Bromodiphenhydramine HCI Sertindole
Bromperidol Sertraline
Brompheniramine Maleate Sibutramine HCI
BTCP HCI Siramesine hydrochloride
Buclizine HCI SKF-525A HCI
Buflomedil HCI SKF-96365 HCI
Bupropion HCI SNC 121
Buspirone HCI Spiperone HCI
Butacaine Sulfate T-226296
Butaclamol HCI, (±)- Tegaserod Maleate
Butenafine HCI Terbinafine HCI
Butoconazole Nitrate Terconazole
BW 723C86 HCI Terfenadine
Carbetapentane Citrate Terfenadine Related Compound A
Carbinoxamine Maleate Tetrindole Mesylate
Carpipramine DiHCI DiH20 Thiethylperazine Malate
Carvedilol Thioperamide Maleate
Cephapirin Benzathine Thioproperazine
CGS-12066A Maleate Thioridazine
Chloroprocaine HCI Thiothixene
Chlorpheniramine Maleate Thiothixene, (E)- Chlorphenoxamine HCI Thonzonium Bromide
Chlorprothixene Tioconazole Related Compound A
Cinanserin HCI TMB-8 HCI
Cinnarizine Tolterodine L-Tartrate
Cirazoline HCI Toremifene Citrate
Cis-(+/-)-N-Methyl-N-[2-(3,4- Tramazoline HCI
Dichlorophenyl)Ethyl]-2-(1 - Pyrrolidinyl)Cyclohexamine DiHBr
Cis(Z)-Flupentixol DiHCI Trans-U-50488 Methanesulfonate, (±)- cis-2-(Cyclopropylmethyl)-7-(4- Tridihexethyl Chloride
fluorobenzoyl)perhydropyrido[1 ,2-a]pyrazine cis-2-[4-(Trifluoromethyl)benzyl]-3a,4,7,7a- Trifluoperazine HCI
tetrahydroisoindoline
Cisapride Hydrate Trifluperidol HCI
Citalopram HBr Trihexyphenidyl HCI
Clemastine Fumarate Trimeprazine Hemi-L-Tartrate
Clemizole HCI Trimipramine Maleate
Clenbuterol HCI Tripelennamine HCI
Clidinium Bromide Triprolidine HCI
Clobenpropit 2HBr Triprolidine HCI Z Isomer
Clofazimine Tropanyl 3,5-Dimethylbenzoate
Clofilium Tosylate Tropine 2-(4-Chlorophenoxy)Butanoate,
Maleate
Clomiphene Citrate U-50488 HCI, (-)-
Clomiphene Related Compound A U-62066 Clomipramine UH 232 Maleate, (+)-
Cloperastine HCI Vesamicol HCI
Clorgyline HCI Vinpocetine
Clozapine W-7 HCI
Conessine WB-4101 HCI
Preferably, the table above includes also reduced haloperidol. Reduced haloperidol is an active metabolite of haloperidol that is produced in humans, shows a high affinity (in the low nanomolar range) for sigma-1 receptors, and produces an irreversible blockade of sigma-1 receptors both in experimental animals and human cells.
Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art (e.g. in Krogsgaard-Larsen et al., Textbook of Drug design and Discovery, Taylor & Francis (April 2002)).
In a preferred embodiment, the sigma ligand in the context of the present invention has the general formula (I) as depicted above.
In a preferred embodiment, in the compounds of formula (I) is selected from H, - COR8, and substituted or unsubstituted alkyl. More preferably, is selected from H, methyl and acetyl. A more preferred embodiment is when is H.
In another preferred embodiment, R2 in the compounds of formula (I) represents H or alkyl, more preferably methyl.
In yet another preferred embodiment of the invention, R3 and R4 in the compounds of formula (I) are situated in the meta and para positions of the phenyl group, and preferably, they are selected independently from halogen and substituted or unsubstituted alkyl. In an especially preferred embodiment of the invention, in the compounds of formula (I) both R3 and R4 together with the phenyl group form an optionally substituted fused ring system (for example, a substituted or unsubstituted aryl group or a substituted or unsubsituted, aromatic or non-aromatic heterocyclyl group may be fused), more preferably, a naphthyl ring system. Also in the compounds of formula (I), embodiments where n is selected from 2, 3, 4 are preferred in the context of the present invention, more preferably n is 2.
Finally, in another embodiment it is preferred in the compounds of formula (I) that R5 and R6 are, each independently, Ci_6 alkyl, or together with the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclyl group a, in particular a group chosen among morpholinyl, piperidinyl, and pyrrolidinyl group. More preferably, R5 and R6 together form a morpholine-4-yl group.
In preferred variants of the invention, the sigma ligand of formula (I) is selected from:
[I] 4-{2-(1 -(3,4-dichlorophenyl)-5-methyl-1 H pyrazol-3-yloxy)ethyl}morpholine [2] 2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine
[3] 1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole
[4] 1-(3,4-Dichlorophenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole
[5] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperidine
[6] 1-{2-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole [7] 3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H- imidazo[4,5-b]pyridine
[8]1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-4-methylpiperazine
[9] Ethyl 4-{2-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperazine carboxylate [10] 1-(4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl)piperazin-1- yl)ethanone
[I I] 4-{2-[1-(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}morpholine [12] 1-(4-Methoxyphenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole [13] 1-(4-Methoxyphenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole [14] 1-[2-(1-(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl]piperidine
[15] 1-{2-[1-(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole [16] 4-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}morpholine
[17] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole
[18] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole
[19] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}piperidine [20] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole
[21]2-{2-[1-(3,4-dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}-1 , 2,3,4- tetrahydroisoquinoline
[22] 4-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}morpholine
[23] 1-(3,4-Dichlorophenyl)-5-methyl-3-[4-(pyrrolidin-1-yl)butoxy]-1 H-pyrazole [24] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}piperidine
[25]1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-4-methylpiperazine
[26] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-1 H-imidazole
[27] 4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]-N,N-diethylbutan-1 -amine
[28]1-{4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-4-phenylpiperidine [29] 1-{4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-6,7-dihydro-1 H- indol-4(5H)-one
[30] 2-{4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-1 ,2,3,4- tetrahydroisoquinoline
[31] 4-{2-[1-(3,4-dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}morpholine [32]2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine [33] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole [34] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole [35] 1-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}piperidine [36] 2-{2-[1-(3,4-dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}-1 ,2,3,4- tetrahydroisoquinoline
[37] 4-{2-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]ethyl}morpholine [38] 2-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy] N,N-diethylethanamine [39] 1-(3,4-dichlorophenyl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole [40] 1-{2-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]ethyl}piperidine [41] 1 -(3, 4-dichlorophenyl)-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole [42]1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperazine [43] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}pyrrolidin-3-amine [44]4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}morpholine [45]4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}morpholine [46]2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine [47] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole [48] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole [49] 1-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}piperidine
[50] 4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}morpholine
[51](2S,6R)-4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}-2,6- dimethylmorpholine
[52] 1-{4-[1-(3,4-Dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}piperidine [53] 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1 H-pyrazole
[55] 4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N,N-diethylbutan-1 -amine
[56] N-benzyl-4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N-methylbutan-1 -amine
[57]4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1- amine [58] 4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}thiomorpholine
[59]1-[1-(3,4-Dichlorophenyl)-5-methyl-3-(2-morpholinoethoxy)-1 H-pyrazol-4- yl]ethanone
[60]1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazol-4- yl}ethanone
[61] 1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(piperidin-1-yl)ethoxy]-1 H-pyrazol-4- yl}ethanone
[62] 1-{1-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethoxy]-5-methyl-1 H-pyrazol-4- yl}ethanone [63] 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholine
[64] N,N-Diethyl-2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethanamine [65] 1-{2-[5-Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}piperidine [66] 5-Methyl-1-(naphthalen-2-yl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole or their pharmaceutically acceptable salts, isomers, prodrugs or solvates.
In a more preferred variant of the invention, the sigma ligand of formula (I) is 4-{2-[5- Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl} morpholine. This particular compound is designated in the examples of the present invention as compound 63.
The compounds of formula (I) and their salts or solvates can be prepared as disclosed in the previous application WO2006/021462.
As stated previously, one aspect of this invention refers to the use of sigma ligand as defined above for the manufacture of a medicament for the prevention and/or treatment of OIH associated to opioid therapy.
According to the IASP "hyperalgesia" is defined as "an increased response to a stimulus which is normally painful" (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 211). As noted previously, opioid-induced hyperalgesia or opioid-induced abnormal pain sensitivity is a phenomenon associated with the use of opioids such as morphine, hydrocodone, remifentanyl, oxycodone or methadone. Individuals taking opioids can develop an increasing sensitivity to noxious stimuli, even evolving a painful response to previously non-noxious stimuli (allodynia). Some studies demonstrated that this effect occurs not only after long use of opioids but also after only a single high dose of opioids. Although tolerance and opioid-induced hyperalgesia both result in a similar need for dose escalation, they are nevertheless caused by two distinct mechanisms. The similar net effect makes the two phenomena difficult to distinguish in a clinical setting. Under chronic opioid treatment, a particular individual's requirement for dose escalation may be due to tolerance (desensitization of antinociceptive mechanisms), opioid-induced hyperalgesia (sensitization of pronociceptive mechanisms), or a combination of both. Identifying the development of hyperalgesia is of great clinical importance since patients receiving opioids to relieve pain may paradoxically experience more pain as a result of treatment. Whereas increasing the dose of opioid can be an effective way to overcome tolerance, doing so to compensate for opioid- induced hyperalgesia may worsen the patient's condition by increasing sensitivity to pain while escalating physical dependence. If an individual is taking opioids for a chronic pain condition, and cannot achieve effective pain relief despite increases in dose, they may be experiencing opioid-induced hyperalgesia.
The invention is also directed to a combination of at least one sigma ligand as defined above and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of opioid-induced hyperalgesia associated to opioid therapy. Compounds that bind to the opioid receptor within the scope of the present invention include natural opiates, such as morphine, codeine and thebaine; semi-synthetic opiates, derived from the natural opioids, such as hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmorphine, nicomorphine, dipropanoylmorphine, benzylmorphine and ethylmorphine; fully synthetic opioids, such as fentanyl, pethidine, methadone, tramadol and propoxyphene; and endogenous opioid peptides, produced naturally in the body, such as endorphins, enkephalins, dynorphins, and endomorphins and their analogues. Preferably, the combination according to this invention comprises morphine or its analogues. The combination of the invention may be formulated for its simultaneous separate or sequential administration, with at least a pharmaceutically acceptable carrier, additive, adjuvant or vehicle. This has the implication that the combination of the two active compounds may be administered: a) As a combination that is being part of the same medicament formulation, the two active compounds being then administered always simultaneously. b) As a combination of two units, each with one of the active substances giving rise to the possibility of simultaneous, sequential or separate administration. In a particular embodiment, the sigma ligand is independently administered from the opioid or opiate (i.e in two units) but at the same time. In another particular embodiment, the sigma ligand is administered first, and then the opioid or opiate is separately or sequentially administered. In yet another particular embodiment, the opioid or opiate is administered first, and then the sigma ligand is administered, separately or sequentially, as defined. The auxiliary materials or additives of a pharmaceutical composition according to the present invention (i.e. a composition comprising at least one sigma ligand or a composition comprising at least one sigma ligand and at least one opioid or opiate compound) can be selected among carriers, excipients, support materials, lubricants, fillers, solvents, diluents, colorants, flavour conditioners such as sugars, antioxidants, binders, adhesives, disintegrants, anti-adherents, glidants and/or agglutinants. In the case of suppositories, this may imply waxes or fatty acid esters or preservatives, emulsifiers and/or carriers for parenteral application. The selection of these auxiliary materials and/or additives and the amounts to be used will depend on the form of application of the pharmaceutical composition. The pharmaceutical composition in accordance with the invention can be adapted to any form of administration, be it orally or parenterally, for example pulmonar, nasally, rectally and/or intravenously. Therefore, the formulation in accordance with the invention may be adapted for topical or systemic application, particularly for dermal, transdermal, subcutaneous, intramuscular, intra-articular, intraperitoneal, intravenous, intra-arterial , intravesical , intraosseous, intracavernosal , pul monary, buccal , sublingual, ocular, intravitreal, intranasal, percutaneous, rectal, vaginal, oral, epidural, intrathecal, intraventricular, intracerebral, intracerebroventricular, intracisternal, intraspinal, perispinal, intracranial, delivery via needles or catheters with or without pump devices, or other application routes.
Suitable preparations for oral applications are tablets, pills, caplets, gel caps, chewing gums, capsules, granules, drops or syrups. Suitable preparations for parenteral applications are solutions, suspensions, reconstitutable dry preparations, aerosols or sprays.
The composition of the invention may be formulated as deposits in dissolved form or in patches, for percutaneous application.
Skin applications include ointments, gels, creams, lotions, suspensions or emulsions. Suitable form of rectal application is by means of suppositories.
Moreover, the composition may be presented in a form suitable for once daily, weekly, or monthly administration.
Accordingly, in another aspect the invention provides a method of treatment of a patient, notably a human, suffering from OIH associated to opioid therapy, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand as defined above.
In certain embodiments, hyperalgesia is suppressed, ameliorated and/or prevented. In certain embodiments, the sigma ligand can be administered prior to an activity likely to result in hyperalgesia, i.e. opioid administration. For example, the formulation can be administered 30 minutes, 1 hour, 2 hours, 5 hours, 10 hours, 15 hours, 24 hours or even more, such as 1 day, several days, or even a week, two weeks, three weeks, or more prior to the activity likely to result in hyperalgesia, i.e. prior to opioid administration. In other embodiments, the sigma ligand can be administered during and/or after the administration of the opioid. In some instances, the sigma ligand is administered 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 30 hours, 36 hours, or more, after the administration of the opioid.
In one embodiment of the invention it is preferred that the sigma ligand is used in therapeutically effective amounts. The physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of condition being treated. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached. When the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents.
For example, the dosage regime that must be administered to the patient will depend on the patient's weight, the type of application, the condition and severity of the disease. A preferred dosage regime of comprises an administration of a compound according the present invention within a range of 0.01 to 300 mg/kg, more preferably 0.01 to 100 mg/kg, and most preferable 0.01 to 50 mg/kg.
The following examples are merely illustrative of certain embodiments of the invention and cannot be considered as restricting it in any way.
Examples
Example 1. Synthesis of 4-{2-[5-Methyl-1 -(naphthalen-2-yl)-1 H-pyrazol-3- yloxy]ethyl} morpholine (compound 63) and its hydrochloride salt
Figure imgf000040_0001
Compound 63 Compound 63 HCI
Compound 63 can be can be prepared as disclosed in the previous application WO2006/021462. Its hydrochloride can be obtained according the following procedure:
Compound 63 (6,39 g) was dissolved in ethanol saturated with HCI, the mixture was stirred then for some minutes and evaporated to dryness. The residue was crystallized from isopropanol. The mother liquors from the first crystallization afforded a second crystallization by concentrating. Both crystallizations taken together yielded 5.24 g (63 %) of the corresponding hydrochloride salt (m.p. = 197-199 °C).
1 H-NMR (DMSO-d6) δ ppm: 10,85 (bs, 1 H), 7,95 (m, 4H), 7,7 (dd, J=2,2, 8,8 Hz, 1 H), 7,55 (m, 2H), 5,9 (s, 1 H), 4,55 (m, 2H), 3,95 (m, 2H), 3,75 (m, 2H), 3,55-3,4 (m, 4H), 3,2 (m, 2H), 2,35 (s, 3H).
HPLC purity: 99.8%.
Example 2: Modulation on Mechanical Sensitization induced by opioid administration in operated (plantar incision) and naive rats: effect of sigma antagonists
Plantar incision surgery
The incisional pain model was adapted from Brennan et al. (1996). The induction of anaesthesia in rats was performed with 3% isofluoran for veterinary use, employing an Ohmeda vaporizer and an anaesthesia chamber. Anaesthesia was kept during the surgical operation by a tube which directs the isofluran vapours to the animal's snout. Once the rats were anaesthetised, they were laid down in a prone position and their right hindpaws were cleaned out with alcohol.
Then, a skin incision in the hind paw of about 10 mm was made by means of a scalpel, starting about 5 mm from the heel and extending toward the toes. Fascia was located and by means of curve scissors muscle was elevated and a longitudinal incision of about 5 mm was made, thus the muscle origin and insertion remained intact.
Therefore, both superficial (skin) and deep (muscle) tissues and nerves were injured.
The skin of the paw was stitched with a suturing stitch with breaded silk (3.0) and the wound was cleaned out with iodinated povidone.
Behavioural test
Mechanical allodynia was tested using von Frey filaments: Animals were placed in methacrylate cylinders on an elevated surface, with metallic mesh floor perforated in order to apply the filaments. After an acclimation period of about 30 minutes within the cylinders, both hindpaws were stimulated (the injured and the non-injured paw, serving the latter as control), starting with the lowest force filament (0.4 g) and reaching a 15 g filament. The animal's response to pain was manifested by the withdrawal of the paw as a consequence of the painful stimulus caused by a filament. The pressure (force in grams) threshold eliciting the withdrawal of the paw was recorded.
Experimental protocol 1: Coadministration studies in operated rats
The effect of opioids (morphine, remifentanil, fentanyl or sufentanil) and sigma antagonists (compound 63 or BD-1063) in operated rats were evaluated in a co- treatment paradigm as fol lows: the opioid drug is adm inistrated through the intraperitoneal route in three consecutive administrations: at the time of surgery, 15 minutes later and 30 minutes after surgery. The sigma antagonist is administrated only once either 30 minutes before surgery (paradigm 1) or 30 minutes after surgery (paradigm 2). Figure 1 is a schematic representation showing the time course for the two paradigms followed in experimental protocol n° 1.
The doses of remifentanil per administration were 0.066 mg/kg each time (0.2 mg/kg total). The doses of morphine were 3.3 mg/kg each time (10 mg/kg in total). The doses of fentanyl per administration were 0.16 mg/kg each time (0.48 mg/kg total). The doses of sufentanil per administration were 0.05 mg/kg each time (0.15 mg/kg total). The doses used for the single administration of sigma antagonist (BD-1063 and compound 63) were 20, 40 and 80 mg/kg.
Assessment of mechanical allodynia was done 4, 24, 48, 72 and 96 hours after surgery. Additional evaluations were performed on days 5, 6, 7 and 8 after surgery when coadministration of compound 63 and opioids were assessed. The results are shown in Figures 2-5 and 10-11.
As expected, the plantar incision surgery produced a significant decrease of the mechanical sensitization threshold as measured with the von Frey filaments application (tactile allodynia for 2 days; figures 2-5) in control rats (vehicle group) that almost recovered their normal threshold at day 3-4. Opioid administration (remiphentanyl in figures 2 and 3; morphine in figures 4 and 5; fentanyl in figure 10; sufentanil in figure 1 1) initially induced an analgesic effect 4 hours after operation. However, the analgesic effect disappeared 24 hours later and consecutive daily measurements of paw withdrawal showed an enhancement of tactile allodynia (that is 01 H) respect to vehicle treatment that is evidenciable from day 3 to day 6-7.
Administration of 20 mg/kg of compound n° 63 during the perioperative period on day 0 strongly reduced the enhancement of allodynia induced by perioperative remiphentanyl (figures 2 and 3), morphine (figure 4), fentanyl (figure 10) and sufentanil (figure 1 1 ) administration. Furthermore, 40 and 80 mg/kg of compound n° 63 also inhibit dose- dependently the decrease of the mechanical sensitization threshold induced by the surgery.
Administration of 80 mg/kg of BD-1063 during the perioperative period on day 0 strongly reduced the enhancement of allodynia induced by perioperative morphine (figure 5) administration.
Altogether, data obtained following this experimental approach (perioperative coadministration of sigma ligands and opioids) indicate that sigma ligands are able to prevent the development of OIH.
Experimental protocol 2: OIH precipitated by naloxone
In the previous study (experimental protocol 1), it has been shown that the perioperative administration of morphine, fentanyl, sufentanil or remifentanil enhances the extent and duration of postoperative pain (hyperalgesia). In contrast, the co- administration of compound n° 63 inhibits dose-dependently the development of OIH. To further study the effect on OIH, the mechanical threshold in these opioid-treated rats was evaluated by administering naloxone since naloxone-precipitated opioid abstinence is associated with an enhancement of reflex responses to noxious stimulation (hyperalgesia). Thus, when rats had recovered their pre-drug nociceptive threshold value after the opioid or co-administration treatment (21 days later), the ability of naloxone to precipitate hyperalgesia in rats was tested by measuring the withdrawal responses using the von Frey filaments. _Figure 12 is a schematic representation showing the time course for experimental protocol n° 2. The long lasting effects of morphine, remifentanil, fentanyl and sufentanil, and the effects of compound n° 63 co-administration on pharmacological effects of the opioids were studied following this protocol. In particular, the treatment schedule was as follows: morphine (3.3 mg/kg), remifentanil (0.2 mg/kg), fentanyl (0.16 mg/kg), sufentanil (0.05 mg/kg) or vehicle was injected three times every 15 min starting at the time of plantar incision. The single injection of compound n° 63 was co-administered with the last dose of opioid. At the end of these experiments, on day 21 , all rats received a naloxone injection (2 mg/kg), and the nociceptive threshold was measured 1 , 24 and 48 hours later (see Figures 13-16).
As shown above in experimental protocol 1 , the nociceptive threshold was returned to basal 10 days after opioids administrations. The injection of naloxone on day 21 (11 days after the animals had completely recovered their pre-drug nociceptive threshold value) induced a significant decrease in the nociceptive threshold below the basal value. On the other hand, no significant effect of naloxone was observed in vehicle saline-treated rats. Moreover, naloxone was also unable to precipitate hyperalgesia when it was injected on day 21 in opioid-treated rats that had been co-administrated with 80 mg/kg of compound n° 63 (20 and 40 mg/kg produced an attenuation of naloxone-precipitated hyperalgesia) (see Figures 13-16).
Experimental protocol 3: Coadministration studies in naive rats.
The effect of opioids (morphine or remiphentanyl) and sigma antagonists (compound 63 or BD-1063) i n na ive rats was evaluated in a co-treatment paradigm by intraperitoneal administration at the same time (figure 6).
Naive rats were administrated with 0.3 mg/kg of remifentanil or 10 mg/kg of morphine. The doses of BD-1063 or compound n° 63 were 20, 40 and 80 mg/kg.
Assessment of mechanical allodynia was done 4, 24, 48 and 72 hours after surgery. The results are shown in Figures 7-9.
Opioid administration to naive rats produces, 24 hours after, a significant decrease of the mechanical threshold (that is OIH) as measured with the von Frey filaments application (tactile allodynia for 2 days; figures 7-9). Three days later rats recovered their normal threshold. Compound n° 63 coadministration reduces dose-dependently the enhancement of allodynia induced by remifentanil administration (figure 7). BD-1063 coadministration also reduces the enhancement of allodynia induced by remifentanil (figure 8) and morphine (figure 9) administration.
Altogether, data obtained following this experimental approach (co-administration of sigma ligands and opioids to naive rats) indicate that opioids induce OIH, evidenciable from day 1-2 after opioid administration, and that the co-administration of sigma ligands prevents the development of OIH.

Claims

1. A sigma ligand for use in the prevention and/or treatment of opioid-induced hyperalgesia associated to opioid therapy.
2. Sigma ligand for use according to claim 1 , wherein the sigma ligand is selected from the group consisting of a sigma receptor antagonist, preferably selected from a neutral antagonist, an inverse agonist, or a partial antagonist.
3. Sigma ligand for use according to any preceding claim, having the general formula (I):
Figure imgf000046_0001
(I)
wherein
Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl , substituted or unsubstituted aromatic heterocyclyl , substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, - C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, - NR8C(0)R9, -N02, -N=CR8R9, and halogen; R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non- aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, - COR8, -C(0)OR8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t- R8, -NR8R9, -NR8C(0)R9, -N02, -N=CR8R9, and halogen;
R3 and R4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted al kenyl , su bstituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -N02, -N=CR8R9, and halogen, or together they form an optionally substituted fused ring system;
R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -COR8, -C(0)OR8, -C(0)NR8R9, -CH=NR8, -CN, -OR8, -OC(0)R8, -S(0)t-R8 , -NR8R9, -NR8C(0)R9, -N02, -N=CR8R9, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group; n is selected from 1 , 2, 3,
4, 5, 6, 7 and 8; t is 1 ,2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen; or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof. Sigma ligand for use according to claim 3, wherein is selected from H, -COR8 and substituted or unsubstituted alkyl.
5. Sigma ligand for use according to claims 3 or 4, wherein R2 is H or alkyl.
6. Sigma ligand for use according to any of claims 3 to 5, wherein R3 and R4 together form a fused naphthyl ring system.
7. Sigma ligand for use according to any of claims 3 to 6, wherein R5 and R6 together form a morpholine-4-yl group.
8. Sigma ligand for use according to any preceding claim, which is selected from the group consisting of:
4-{2-(1 -(3,4-dichlorophenyl)-5-methyl-1 H pyrazol-3-yloxy)ethyl}morpholine,
2- [1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine, 1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-(3,4-Dichlorophenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperidine,
1-{2-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole,
3- {1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H- imidazo[4,5-b]pyridine,
1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-4-methylpiperazine,
Ethyl 4-{2-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperazine carboxylate,
1-(4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl)piperazin-1- yl)ethanone,
4- {2-[1-(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}morpholine,
1-(4-Methoxyphenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-(4-Methoxyphenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1 -[2-(1 -(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy)ethyl]piperidine,
1-{2-[1-(4-Methoxyphenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole,
4-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}morpholine,
1-(3,4-Dichlorophenyl)-5-phenyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-(3,4-Dichlorophenyl)-5-phenyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}piperidine, 1- {2-[1-(3,4-Dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}-1 H-imidazole,
2- {2-[1-(3,4-dichlorophenyl)-5-phenyl-1 H-pyrazol-3-yloxy]ethyl}-1 , 2,3,4- tetrahydroisoquinoline,
4-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}morpholine,
1-(3,4-Dichlorophenyl)-5-methyl-3-[4-(pyrrolidin-1-yl)butoxy]-1 H-pyrazole,
1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}piperidine,
1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-4-methylpiperazine, 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-1 H-imidazole, 4-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]-N,N-diethylbutan-1 -amine, 1-{4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-4-phenylpiperidine,
1- {4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-6,7-dihydro-1 H-indol- 4(5H)-one,
2- {4-[1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]butyl}-1 , 2,3,4- tetrahydroisoquinoline,
4-{2-[1 -(3,4-dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}morpholine,
2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine,
1-(3,4-Dichlorophenyl)-5-isopropyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-(3,4-Dichlorophenyl)-5-isopropyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1- {2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}piperidine, 2-{2-[1-(3,4-dichlorophenyl)-5-isopropyl-1 H-pyrazol-3-yloxy]ethyl}-1 ,2,3,4- tetrahydroisoquinoline,
4-{2-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]ethyl}morpholine,
2- [1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy] N,N-diethylethanamine,
1-(3,4-dichlorophenyl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-{2-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]ethyl}piperidine,
1-(3,4-dichlorophenyl)-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}piperazine,
1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1 H-pyrazol-3-yloxy]ethyl}pyrrolidin-3-amine, 4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}morpholine,
4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}morpholine,
2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]-N,N-diethylethanamine,
1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1 H-pyrazole,
1-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yloxy]ethyl}piperidine,
4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}morpholine,
(2S,6R)-4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}-2,6-dimethylmorpholine,
1-{4-[1-(3,4-Dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}piperidine,
1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1 H-pyrazole,
4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N,N-diethylbutan-1 -amine,
N-benzyl-4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N-methylbutan-1 -amine,
4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1- amine,
4-{4-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yloxy]butyl}thiomorpholine,
1-[1-(3,4-Dichlorophenyl)-5-methyl-3-(2-morpholinoethoxy)-1 H-pyrazol-4-yl]ethanone,
1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazol-4- yl}ethanone,
1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(piperidin-1-yl)ethoxy]-1 H-pyrazol-4- yl}ethanone,
1-{1-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethoxy]-5-methyl-1 H-pyrazol-4- yl}ethanone,
4- {2-[5-Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholine,
N,N-Diethyl-2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethanamine,
1-{2-[5-Methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}piperidine, and
5- Methyl-1-(naphthalen-2-yl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1 H-pyrazole,
or a pharmaceutically acceptable salt, prodrug or solvate thereof.
9. Sigma ligand for use according to any of claims 3 to 8, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl} morpholine, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.
10. Sigma ligand for use according to claim 9, wherein the sigma ligand is 4-{2-[5- methyl-1-(naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride.
11. A combination of at least one sigma ligand as defined in any preceding claim and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of opioid-induced hyperalgesia associated to opioid therapy.
12. A method of treatment of a patient suffering from OIH associated to opioid therapy, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand.
PCT/EP2011/063286 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia WO2012016980A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
UAA201302559A UA110213C2 (en) 2010-08-03 2011-02-08 Use of sigma-ligand induced opioid hyperalgesia
MX2013001328A MX350828B (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia.
EP11738245.7A EP2600863B1 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
AU2011287627A AU2011287627B2 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
SG2013007752A SG187668A1 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
CN201180038322XA CN103052388A (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
CA2807069A CA2807069C (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
JP2013522233A JP5923502B2 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
ES11738245.7T ES2673729T3 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
NZ606539A NZ606539A (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
RU2013109291/15A RU2589899C2 (en) 2010-08-03 2011-08-02 Use of sigma ligands with induced opioids hyperalgesia
BR112013002541A BR112013002541A2 (en) 2010-08-03 2011-08-02 use of sigma ligand, combination of at least one sigma ligand and at least one opioid or opiate compound for simultaneous, separate or sequential administration and method of treating a patient suffering from opioid therapy associated with oih
US13/814,148 US9789115B2 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
KR1020137005269A KR101855357B1 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia
MA35700A MA34506B1 (en) 2010-08-03 2011-08-02 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGIA
TNP2013000026A TN2013000026A1 (en) 2011-08-02 2013-01-28 Use of sigma ligands in opioid - induced hyperalgesia
ZA2013/00795A ZA201300795B (en) 2010-08-03 2013-01-30 Use of sigma ligands in opioid-induced hyperalgesia
IL224530A IL224530A (en) 2010-08-03 2013-01-31 Use of a sigma ligand or a combination thereof for prevention and/or treatment of opioid-induced hyperalgesia associated with opioid therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382215.1 2010-08-03
EP10382215A EP2415471A1 (en) 2010-08-03 2010-08-03 Use of sigma ligands in opioid-induced hyperalgesia

Publications (2)

Publication Number Publication Date
WO2012016980A2 true WO2012016980A2 (en) 2012-02-09
WO2012016980A3 WO2012016980A3 (en) 2012-03-29

Family

ID=42763359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/063286 WO2012016980A2 (en) 2010-08-03 2011-08-02 Use of sigma ligands in opioid-induced hyperalgesia

Country Status (22)

Country Link
US (1) US9789115B2 (en)
EP (2) EP2415471A1 (en)
JP (1) JP5923502B2 (en)
KR (1) KR101855357B1 (en)
CN (2) CN103052388A (en)
AR (1) AR082441A1 (en)
AU (1) AU2011287627B2 (en)
BR (1) BR112013002541A2 (en)
CA (1) CA2807069C (en)
CO (1) CO6680628A2 (en)
ES (1) ES2673729T3 (en)
IL (1) IL224530A (en)
MA (1) MA34506B1 (en)
MX (1) MX350828B (en)
NZ (1) NZ606539A (en)
PT (1) PT2600863T (en)
RU (1) RU2589899C2 (en)
SG (1) SG187668A1 (en)
TW (1) TWI511730B (en)
UA (1) UA110213C2 (en)
WO (1) WO2012016980A2 (en)
ZA (1) ZA201300795B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
WO2015091505A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
EP3389657A4 (en) * 2015-12-14 2019-08-07 Trevena, Inc. Methods of treating hyperalgesia
US11077098B2 (en) 2011-03-23 2021-08-03 Trevena, Inc. Opioid receptor ligands and methods of using and making same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
DE102011117128A1 (en) * 2011-10-28 2013-05-02 Christian-Albrechts-Universität Zu Kiel Compounds for the treatment of influenza
MA41177A (en) * 2014-12-15 2017-10-24 Esteve Labor Dr USE OF SIGMA RECEPTOR LIGANDS IN ARTHROSIS
EP3563848A1 (en) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Serpin inhibitors for the treatment of prion and prion-like diseases
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021462A1 (en) 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
WO2009130310A1 (en) 2008-04-25 2009-10-29 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (en) 1927-03-29 1929-09-30 В.С. Григорьев Anthracene cleaning method
US2908677A (en) 1955-03-30 1959-10-13 Eastman Kodak Co Nickel and cobalt complexes of pyrazolone monoazo compounds
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
CH471199A (en) 1965-07-06 1969-04-15 Sandoz Ag Process for the production of metal-containing azo dyes
DE2313722C3 (en) 1973-03-20 1987-04-16 Bayer Ag, 5090 Leverkusen Chromic complex dye and its use for dyeing and printing nitrogen-containing fibre materials
IT1005472B (en) 1974-02-15 1976-08-20 Montedison Spa PROCEDURE FOR THE PREPARATION OF 2,5, DIMETHYL 3,2H, FURANONE
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
FR2301250A1 (en) 1975-02-21 1976-09-17 Bellon Labor Sa Roger 3-Omega dialkyl amino alkoxy 1,4-diaryl 1H-pyrazoles - analgesics and antiinflammatories prepd. from 3-hydroxy pyrazoles and alkyl halides
CA1121651A (en) 1978-07-27 1982-04-13 Chi-Kuen Shu 2,5-dialkyl dihydrofuranones and 2,4,5-trialkyl dihydrofuranones, mixtures of same and organoleptic uses thereof
US4207392A (en) 1978-10-30 1980-06-10 Eastman Kodak Company Heat developable and stabilizable photographic materials and process
FR2460299A1 (en) 1979-07-05 1981-01-23 Bellon Labor Sa Roger NOVEL DERIVATIVES OF PYRAZOLE AND THEIR THERAPEUTIC APPLICATION
US4234616A (en) 1979-08-03 1980-11-18 International Flavors & Fragrances Inc. Flavoring with mixtures of 2,5-dialkyl dihydrofuranones and 2,4,5-trialkyl dihydrofuranones
FR2472564A1 (en) 1979-12-31 1981-07-03 Bellon Labor Sa Roger 1-Aryl-4-aryl:sulphonyl-3-amino-propoxy-1H-pyrazole derivs. - hypolipaemics and hypocholesterolaemics of low toxicity and non-ulcerogenic
US4826868A (en) 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JPH03232817A (en) 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk Application agent
EP0445974A3 (en) 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
JPH04364129A (en) 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd 6-substituted alkoxyquinoxaline derivative-containing medicinal composition and its production
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5240925A (en) 1991-08-26 1993-08-31 Rohm And Haas Company Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles
RU94046105A (en) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) ANALOGS OF γ-AMINOBUTYRIC ACID AND L-GLUTAMIC ACID AND METHODS OF THEIR SYNTHESIS
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
JPH1036259A (en) 1996-04-11 1998-02-10 Kikkoman Corp Preventive and therapeutic agent for cataract
JPH1055048A (en) 1996-08-08 1998-02-24 Fuji Photo Film Co Ltd Silver halide photograhic sensitive material
WO1998031227A1 (en) 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
ES2201482T3 (en) 1997-04-14 2004-03-16 Ufc Limited DERIVATIVES OF MORPHINE.
TR199903299T2 (en) 1997-07-02 2000-07-21 Merck & Co., Inc. Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)-(3,5-Bis(trifluorometil) Phenyl)Ethoxy-3-(S)-(4-Floro)Phenyl-4-(3 -5(-okso-1H,4H-1,2,4-Triazolo) metilmorpholin'in polymorphik formu.
BR9813284B1 (en) 1997-10-27 2012-08-21 cyclic amino acids and derivatives thereof useful as pharmaceutical agents and pharmaceutical composition.
US6545022B1 (en) 1997-12-16 2003-04-08 Pfizer Inc. 4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CN1210268C (en) 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((Cyclo) alkyl substituted-.gamma.-aminobutyric acid derivatives (=GABA analogurs), their preparation and their use in the treatment of neurolog disorders
CA2304974C (en) 1997-12-16 2005-10-25 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1999059409A1 (en) 1998-05-21 1999-11-25 Matsumoto Rae R Compounds and uses thereof
CA2322558C (en) 1998-05-26 2006-04-11 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
US6166072A (en) 1998-08-03 2000-12-26 Allelix Neuroscience, Inc. Amino acid derivatives
AU9553898A (en) 1998-10-01 2000-04-26 Egis Gyogyszergyar Rt. Pharmaceutical compositions containing an opiate analgesic and a synergizing substance
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE69934902T2 (en) 1998-11-09 2007-10-18 Santen Pharmaceutical Co., Ltd MEDICAMENT AGAINST DRUG DEPENDENCE
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
NO310544B1 (en) 1999-01-04 2001-07-23 Algeta As Preparation and use of radium-223 for the preparation of preparations and kits for the treatment of calcified tissue for palliation, bone cancer therapy and / or bone surface treatment
EP1180094B1 (en) 1999-05-26 2004-07-28 Warner-Lambert Company Fused polycyclic amino acids as pharmaceutical agents
BR0011039A (en) 1999-05-28 2002-02-26 Warner Lambert Co Gaba analogs replaced with 3-heteroarylalkyl
DE60000833T2 (en) 1999-06-02 2003-09-18 Warner-Lambert Co., Morris Plains AMINO HETEROCYCLES FOR USE AS PHARMACEUTICAL AGENTS
US7091257B2 (en) 1999-07-27 2006-08-15 Alcatel Radiation-curable composition with simultaneous color formation during cure
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2001064670A1 (en) 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
EP1272567A2 (en) 2000-04-03 2003-01-08 Sun Chemical Corporation Mono- and bis-hydrazone pigments
BR0208922A (en) 2001-04-19 2004-04-20 Warner Lambert Co Fused Bicyclic or Tricyclic Amino Acids
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
RU2218187C2 (en) 2002-02-11 2003-12-10 Ростовский научно-исследовательский онкологический институт Method for treating the cases of pain syndrome in oncological patients
GB0206505D0 (en) 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
ATE469143T1 (en) 2002-11-15 2010-06-15 Du Pont NEW ANTHRANILAMIDE TYPE INSECTICIDES
JP2004196678A (en) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd Pyrazole-based derivative
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
WO2005061462A2 (en) 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
JP2008507489A (en) 2004-07-24 2008-03-13 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Use of sigma receptor active compounds for the treatment of mechanical allodynia
SI1781618T1 (en) 2004-08-27 2013-01-31 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
ES2251316B1 (en) 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. SIGMA RECEIVER INHIBITORS.
EP1634872A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
AU2005276591B2 (en) 2004-08-27 2011-03-31 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1632227A1 (en) 2004-09-07 2006-03-08 Laboratorios del Dr. Esteve S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction
US7375219B2 (en) * 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US20080161604A1 (en) 2005-04-26 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
JP2008179541A (en) 2005-05-02 2008-08-07 Mochida Pharmaceut Co Ltd Therapeutic agent for neuropathic pain
ITRM20050332A1 (en) 2005-06-24 2006-12-25 Lay Line Genomics Spa USE OF MOLECULES ABLE TO BLOCK TRKA'S ACTIVITY TO STRENGTHEN THE EFFECTS OF ANALGESIC OPPIACEI ON PAIN.
ES2525217T3 (en) 2005-06-27 2014-12-19 Exelixis Patent Company Llc LXR modulators based on imidazole
WO2007025613A2 (en) 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
EP1948781B1 (en) 2005-10-22 2009-12-30 Se Joon Park Microorganisms having bad smell removal activity of organic waste and use thereof
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US20090181976A1 (en) 2006-02-28 2009-07-16 Buschmann Helmut H Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome
EP1829875A1 (en) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
US8202872B2 (en) 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829873A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrrazole derivatives as sigma receptors antagonists
JP5017256B2 (en) 2006-03-22 2012-09-05 パナソニック株式会社 Blood test equipment
CN103271920A (en) 2006-03-27 2013-09-04 威克斯医药有限公司 Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
EA200802412A1 (en) 2006-06-08 2009-06-30 Шварц Фарма Аг THERAPEUTIC COMBINATIONS FOR SUPPORTING MEDICAL CONDITIONS
RU2322977C1 (en) 2006-08-01 2008-04-27 Закрытое акционерное общество "Физиофарм" Synthetic analgesic agent and method for treatment based on this agent
EP2066648B1 (en) 2006-08-04 2017-04-12 Laboratorios Del. Dr. Esteve, S.A. Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP1921071A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
US20090018151A1 (en) 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
KR100868353B1 (en) 2007-03-08 2008-11-12 한국화학연구원 Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing them
GB0710981D0 (en) 2007-06-07 2007-07-18 Acacia Pharma Ltd New Therapeutic use
JPWO2009038112A1 (en) 2007-09-21 2011-01-06 塩野義製薬株式会社 Solid preparation containing NPYY5 receptor antagonist
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
EP2090311A1 (en) 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
HUE036546T2 (en) * 2008-02-18 2018-07-30 Esteve Labor Dr Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP2112139A1 (en) 2008-04-25 2009-10-28 Laboratorios Del. Dr. Esteve, S.A. Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
RU2382646C1 (en) * 2008-11-20 2010-02-27 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" Method of prevention and treatment of post-operation pain syndrome in case of vast thoraco-abdominal operations
US8192885B2 (en) 2009-01-26 2012-06-05 GM Global Technology Operations LLC Shutdown strategy for enhanced water management
EP2292236A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2335688A1 (en) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
RS55099B1 (en) 2009-11-25 2016-12-30 Esteve Labor Dr Hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
PT2531177T (en) 2010-02-04 2016-08-17 Esteve Labor Dr 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and solvates
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
US20110269727A1 (en) 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2460804A1 (en) 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
CA2922330A1 (en) 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
JP2016540771A (en) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Combination of serotonin-noradrenaline reuptake inhibitor (SNRI) and sigma receptor ligand
EP3082790A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021462A1 (en) 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
WO2009130310A1 (en) 2008-04-25 2009-10-29 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Design and Applications of Prodrugs", 1985, HARWOOD ACADEMIC PUBLISHERS
"IASP, Classification of chronic pain", 2002, IASP PRESS, pages: 211
ANGST, M.S. ET AL., ANESTHESIOLOGY, vol. 104, 2006, pages 570 - 587
BURGER: "Medicinal Chemistry and Drug Discovery", 2001, WILEY
CHIEN CC, PASTERNAK GW: "Sigma antagonists potentiate opioid analgesia in rats", NEUROSCI LETT, vol. 190, no. 2, 1995, pages 137 - 139, XP002498085, DOI: doi:10.1016/0304-3940(95)11504-P
E. CELERIER ET AL., J. NEUROSCI., vol. 21, 2001, pages 4074 - 4080
G. RONSISVALLE ET AL., PURE APPL. CHEM., vol. 73, 2001, pages 1499 - 1509
GUIGNARD,B. ET AL., ANESTHESIOLOGY, vol. 93, 2000, pages 409 - 417
KROGSGAARD-LARSEN ET AL.: "Textbook of Drug design and Discovery", April 2002, TAYLOR & FRANCIS
M.L.LEITNER, EUR. J. PHARMACOL., vol. 259, 1994, pages 65 - 69
MAO,J., PAIN, vol. 100, 2002, pages 213 - 217
MEI J, PASTERNAK GW: "Sigma 1 receptor modulation of opioid analgesia in the mouse", J PHARMACOL EXP THER., vol. 300, no. 3, 2002, pages 1070 - 1074, XP055362826, DOI: doi:10.1124/jpet.300.3.1070
PRASAD, P.D. ET AL., J. NEUROCHEM., vol. 70, no. 2, 1998, pages 443 - 451
R. QUIRON ET AL., TRENDS PHARMACOL. SCI., vol. 13, 1992, pages 85 - 86
S.B. HELLEWELL, W.D. BOWEN, BRAIN RES, vol. 527, 1990, pages 244 - 253
SANDFORD,M. ET AL., PAIN PHYSICIAN, vol. 12, 2009, pages 679 - 684
SMITH,M.T., ACUTE PAIN, vol. 10, 2008, pages 199 - 200
TRESCOT,A.M. ET AL., PAIN PHYSICIAN, vol. 11, 2008, pages S12 - S16

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US11931350B2 (en) 2011-03-23 2024-03-19 Trevena, Inc. Opioid receptor ligands and methods of using and making same
US11077098B2 (en) 2011-03-23 2021-08-03 Trevena, Inc. Opioid receptor ligands and methods of using and making same
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
WO2014170319A1 (en) * 2013-04-16 2014-10-23 Laboratorios Del Dr. Esteve, S.A. Alpha-2 adrenoceptor and sigma receptor ligand combinations
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20160310501A1 (en) * 2013-12-17 2016-10-27 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
CN105873580B (en) * 2013-12-17 2020-08-25 埃斯蒂维制药有限公司 Compositions of gabapentin-like compounds and sigma receptor ligands
CN105873580A (en) * 2013-12-17 2016-08-17 埃斯蒂维实验室股份有限公司 Gabapentinoids and sigma receptor ligands combinations
WO2015091505A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
EP3389657A4 (en) * 2015-12-14 2019-08-07 Trevena, Inc. Methods of treating hyperalgesia
US10588889B2 (en) 2015-12-14 2020-03-17 Trevena, Inc. Methods of treating hyperalgesia
AU2016372028B2 (en) * 2015-12-14 2022-02-17 Trevena, Inc. Methods of treating hyperalgesia

Also Published As

Publication number Publication date
CA2807069C (en) 2018-12-04
AR082441A1 (en) 2012-12-05
AU2011287627B2 (en) 2016-11-10
CN107417620A (en) 2017-12-01
JP2013532709A (en) 2013-08-19
SG187668A1 (en) 2013-03-28
KR20130105613A (en) 2013-09-25
MA34506B1 (en) 2013-09-02
EP2415471A1 (en) 2012-02-08
KR101855357B1 (en) 2018-05-04
US9789115B2 (en) 2017-10-17
AU2011287627A1 (en) 2013-02-21
TWI511730B (en) 2015-12-11
MX2013001328A (en) 2013-03-08
BR112013002541A2 (en) 2016-05-31
NZ606539A (en) 2014-03-28
RU2589899C2 (en) 2016-07-10
EP2600863A2 (en) 2013-06-12
EP2600863B1 (en) 2018-03-28
JP5923502B2 (en) 2016-05-24
CO6680628A2 (en) 2013-05-31
TW201216964A (en) 2012-05-01
CA2807069A1 (en) 2012-02-09
UA110213C2 (en) 2015-12-10
WO2012016980A3 (en) 2012-03-29
RU2013109291A (en) 2014-09-10
PT2600863T (en) 2018-06-25
ZA201300795B (en) 2014-04-30
ES2673729T3 (en) 2018-06-25
IL224530A (en) 2015-07-30
MX350828B (en) 2017-09-25
CN103052388A (en) 2013-04-17
US20130158033A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
CA2807069C (en) Use of sigma ligands in opioid-induced hyperalgesia
CA2819442C (en) Use of sigma ligands in bone cancer pain
AU2011212389B2 (en) Sigma ligands for use in the prevention and/or treatment of postoperative pain
CA2908926A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
AU2011334880B9 (en) Use of sigma ligands in bone cancer pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180038322.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11738245

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2807069

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12013500203

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 224530

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013522233

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13019557

Country of ref document: CO

Ref document number: MX/A/2013/001328

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011738245

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011287627

Country of ref document: AU

Date of ref document: 20110802

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137005269

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201302559

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2013109291

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13814148

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013002541

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013002541

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130201